var title_f33_57_34704="Doppler pulmonary vein MR";
var content_f33_57_34704=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77774&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Continuous wave Doppler from the pulmonary vein in mitral regurgitation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 259px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The systolic flow, which is normally dominant, is depressed and the retrograde flow at the time of atrial contraction, which is normally less than the transmitral A wave, is exaggerated.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_57_34704=[""].join("\n");
var outline_f33_57_34704=null;
var title_f33_57_34705="Pancreas divisum with dilation of the dorsal duct";
var content_f33_57_34705=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F72695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F72695&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pancreas divisum with dilation of the dorsal duct",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 433px; height: 504px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopic retrograde cholangiopancreatography (ERCP) of a patient with pancreas divisum shows abnormal dilation of the dorsal duct, consistent with chronic pancreatitis. Patients with ductal dilation are less likely to respond to endoscopic therapy than those with pancreas divisum alone.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: ERCP in Paediatric Practice: Diagnosis and Treatment, Isis Medical Media LTD, Oxford University Press, UK 1997. Copyright &copy;1997 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_57_34705=[""].join("\n");
var outline_f33_57_34705=null;
var title_f33_57_34706="Prepubertal perineal anatomy";
var content_f33_57_34706=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50025&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 532px\">",
"   <div class=\"ttl\">",
"    Prepubertal perineal anatomy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 512px; height: 339px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Emans SJ. Office evaluation of the child and adolescent. In: Emans, Laufer, Goldstein's Pediatric&nbsp;and Adolescent Gynecology, 6th ed, Emans SJ, Laufer MR (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2012. Copyright &copy; 2012 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_57_34706=[""].join("\n");
var outline_f33_57_34706=null;
var title_f33_57_34707="Osteomyelitis in heel";
var content_f33_57_34707=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F78389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F78389&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    Osteomyelitis in the heel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 273px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Sagittal CT image demonstrates cortical fragmentation of the plantar aspect of the calcaneus (white arrows) and adjacent air and soft tissue ulceration.",
"    <br>",
"     (B) Corresponding fluid sensitive STIR (short tau inversion recovery image) demonstrates extensive high signal edema in the calcaneus (asterisk) and again demonstrates posterior plantar ulcer overlying the calcaneus (black arrow).",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"      Courtesy of Perry Horwich, MD.",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_57_34707=[""].join("\n");
var outline_f33_57_34707=null;
var title_f33_57_34708="North American coral snake (Micrurus fulvius) antivenom: Drug information";
var content_f33_57_34708=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   North American coral snake (Micrurus fulvius) antivenom: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/7/22643?source=see_link\">",
"    see \"North American coral snake (Micrurus fulvius) antivenom: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F13265238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Extension of Expiration Dating: Update",
"     </span>",
"     <span class=\"collapsible-date\">",
"      April 2013",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Wyeth Pharmaceuticals (a subsidiary of Pfizer, Inc) has announced that the expiration date of one lot of antivenin, Lot Number 4030024, has been extended through April 30, 2014. In October 2012, Wyeth announced the expiration date of another lot of antivenin, Lot Number 4030026, has been extended to October 31, 2013.  Institutions should retain any remaining inventory of either Lot No. 4030024 or 4030026 until the aforementioned expiration dates. Clinicians should note that due to supply concerns, Pfizer, Inc supplies product only to direct customers on a replacement or emergency basis. To obtain antivenin, Pfizer, Inc may be reached at 800-666-7248; alternatively, clinicians may contact their local Poison Control Center at 800-222-1222 for assistance in locating antivenin. In the event licensed antivenin cannot be secured, an investigational imported antivenin may be available under an Investigational New Drug (IND) protocol with informed consent; for more information contact a local Poison Control Center at 800-222-1222 or the U.S. Food and Drug Administration (FDA) at 800-835-4709 (business hours) or 301-796-8240 (nonbusiness hours).",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F136142\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antivenin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F136133\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Sensitivity testing:",
"     </b>",
"     Intradermal skin test should be performed prior to antivenin administration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <i>",
"      Skin test: Intradermal:",
"     </i>",
"     0.02-0.03 mL of a 1:10 dilution of normal horse serum or antivenin; evaluate against a control test (intradermal injection of NS on the opposite extremity). A 1:100 or greater dilution should be used if the patient&rsquo;s history suggests hypersensitivity.",
"     <b>",
"      Note:",
"     </b>",
"     A positive reaction is an urticarial wheal with or without pseudopodia surrounded by a zone of erythema appearing within 5-30 minutes.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Desensitization:",
"     </b>",
"     <b>",
"      Note:",
"     </b>",
"     In separate vials or syringes, prepare 1:10 and 1:100 dilutions of antivenin in NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     SubQ: Inject 0.1 mL, 0.2 mL, and 0.5 mL of the 1:100 dilution at 15 minute intervals. During this procedure, proceed with the next dose only if a reaction has NOT occurred following the previous dose. Repeat procedure using the 1:10 dilution and then undiluted antivenin. If no reaction has occurred following administration of 0.5 mL of undiluted antivenin, switch to I.M. administration and continue doubling the dose at 15-minute intervals until the entire dose has been administered or administer usual I.V. dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     If a reaction occurs, apply a tourniquet proximal to the injection site and administer epinephrine (1:1000) proximal to the tourniquet or into another extremity. Wait at least 30 minutes; then administer another antivenin injection at the previous dilution which did not evoke a reaction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Micrurus fulvius",
"      </i>",
"     </b>",
"     <b>",
"      (Eastern coral snake) or",
"     </b>",
"     <b>",
"      <i>",
"       M. tener",
"      </i>",
"     </b>",
"     <b>",
"      (Texas coral snake)",
"     </b>",
"     <b>",
"      envenomation:",
"     </b>",
"     I.V.: 3-5 vials by slow injection (dependent on severity of signs/symptoms; some patients may need more than 10 vials)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Each vial of antivenom neutralizes ~2 mg of venom.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F136139\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F136134\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15673205\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15673206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F136122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection, powder for reconstitution: Derived from",
"     <i>",
"      Micrurus fulvius",
"     </i>",
"     venom [equine origin; contains phenol and thimerosal; packaged with diluent] [DSC]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F136110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F136124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Have ready access to medications and equipment for resuscitation. An I.V. infusion of NS 250-500 mL should be started, and the doses of antivenin should be delivered by slow injection or via reservoir bottle. Inject the first 1-2 mL of antivenin over 3-5 minutes with careful observation for the development of hypersensitivity. The rate of infusion for the remaining antivenin will be regulated by tolerance to the antivenin and the severity of envenomation.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F136123\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of envenomation by an Eastern coral snake (",
"     <i>",
"      Micrurus fulvius",
"     </i>",
"     ) or Texas coral snake (",
"     <i>",
"      Micrurus tener",
"     </i>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F136140\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Immediate systemic reactions (allergic, anaphylaxis, shock): May occur within 30 minutes and may start before needle is withdrawn; symptoms include apprehension, cough, collapse, cyanosis, dyspnea, edema (face, throat, tongue), flushing, itching, urticaria, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delayed systemic reactions (serum sickness): Usually occur 5-24 days following administration; symptoms include arthralgia, edema, fever, lymphadenopathy, malaise, urticaria, nausea, vomiting. Neurological symptoms (eg, meningismus, peripheral neuritis, muscle weakness/atrophy, pain) may also occur.",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F136126\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concomitant use with opioid analgesics or other narcotics that depress respiration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Note:",
"     </b>",
"     Hypersensitivity to antivenin (",
"     <i>",
"      Micrurus fulvius",
"     </i>",
"     ) or horse serum (either by history of or as a result of an appropriate sensitivity test) is a relative contraindication.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     In patients with a life-threatening envenomation, there are no contraindications.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F136114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Delayed serum sickness: Delayed serum sickness may occur 1-3 weeks from administration (especially when large doses used) even with a negative allergic history and absence of reaction to skin test.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Horse serum hypersensitivity: Carefully review allergies and history of exposure to products containing horse serum. History of atopic sensitivity to horses may increase risk of immediate sensitivity reactions. Use with caution in patients with asthma, hay fever, or urticaria.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Beta-blockers: Concomitant use with beta-blockers may increase the severity of acute anaphylaxis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sedatives: Use with extreme caution; concomitant use with opioids or other narcotic analgesics that suppress respiration is contraindicated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: North American coral snake envenomation: Do not administer prophylactically to asymptomatic patients. Clinicians should note that antivenin (",
"     <i>",
"      Micrurus fulvius",
"     </i>",
"     ) does not neutralize venom of the Arizona or Sonoran coral snake (",
"     <i>",
"      Micruroides euryxanthus",
"     </i>",
"     ).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Desensitization: A desensitization protocol is available if sensitivity tests are mildly or questionably positive to reduce risk of immediate severe hypersensitivity reaction. According to the manufacturer, desensitization should be performed when antivenin administration would be lifesaving; however, the risk of anaphylaxis should be weighed against the risks associated with delayed antivenin administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Resuscitation precautions: All patients require close monitoring in a setting that has ready access to medications and equipment for resuscitation.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Skin test: The manufacturer recommends that a skin test be performed prior to administration; however, the utility of skin tests to accurately identify patients at risk of early (anaphylactic) or late (serum sickness) hypersensitivity reactions to horse-derived antivenins has been questioned (Klaewsongkram, 2009; WHO, 2005). The absence of a skin hypersensitivity reaction does not exclude anaphylaxis or hypersensitivity following antivenin administration. False-negative rate for skin testing is 10% with similar agents. Conversely, hypersensitivity is not an absolute contraindication in a significantly envenomated patient.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F136117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13265239\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     In general, medications used as antidotes should take into consideration the health and prognosis of the mother.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F13359938\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Resolution of symptoms of envenomation or emergence of symptoms of hypersensitivity to the antivenin; respiratory function and oxygenation; urine for hemoglobinuria",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F136113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Antibodies neutralize the venom components, thereby blocking the effects of the Eastern coral snake (",
"     <i>",
"      Micrurus fulvius",
"     </i>",
"     ) and Texas coral snake (",
"     <i>",
"      Micrurus tener",
"     </i>",
"     ) venom",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      de Roodt AR, Paniagua-Solis JF, Dolab JA, et al, &ldquo;Effectiveness of Two Common Antivenoms for North, Central, and South American",
"      <i>",
"       Micrurus",
"      </i>",
"      Envenomations,&rdquo;",
"      <i>",
"       J Toxicol Clin Toxicol",
"      </i>",
"      , 2004, 42(2):171-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/57/34708/abstract-text/15214622/pubmed\" id=\"15214622\" target=\"_blank\">",
"        15214622",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Food and Drug Administration (FDA), \"Information on the Use of Antivenoms.\" Available at",
"      <a href=\"file://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/InvestigationalNewDrugINDorDeviceExemptionIDEProcess/ucm094321.htm\" target=\"_blank\">",
"       file://www.fda.gov/BiologicsBloodVaccines/DevelopmentApprovalProcess/InvestigationalNewDrugINDorDeviceExemptionIDEProcess/ucm094321.htm",
"      </a>",
"      . Last accessed October 31, 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klaewsongkram J, \"A Role of Snake Antivenom Skin Test From the Allergist's Point of View,\"",
"      <i>",
"       Acta Trop",
"      </i>",
"      , 2009, 109(1):84-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/57/34708/abstract-text/18929526/pubmed\" id=\"18929526\" target=\"_blank\">",
"        18929526",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Norris RL, Pfalzgraf RR, and Laing G, &ldquo;Death Following Coral Snake Bite in the United States-First Documented Case (With ELISA Confirmation of Envenomation) in Over 40 Years,&rdquo;",
"      <i>",
"       Toxicon",
"      </i>",
"      , 2009, 53(6): 693-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/57/34708/abstract-text/19673084/pubmed\" id=\"19673084\" target=\"_blank\">",
"        19673084",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Sanchez EE, Lopez-Johnston  JC, Rodriguez-Acosta A, et al, &ldquo;Neutralization of Two North American Coral Snake Venoms With United States and Mexican Antivenoms,&rdquo;",
"      <i>",
"       Toxicon",
"      </i>",
"      , 2008, 51(2):297-303.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/57/34708/abstract-text/18054059/pubmed\" id=\"18054059\" target=\"_blank\">",
"        18054059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tanaka GD, Furtado Mde F, Portaro FC, et al, &ldquo;Diversity of Micrurus Snake Species Related to Their Venom Toxic Effects and the Prospective of Antivenom Neutralization,&rdquo;",
"      <i>",
"       PLoS Negl Trop Dis",
"      </i>",
"      , 2010, 4(3):e622.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/57/34708/abstract-text/20231886/pubmed\" id=\"20231886\" target=\"_blank\">",
"        20231886",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Walter FG, Stolz U, Shirazi F, et al, &ldquo;Temporal Analyses of Coral Snakebite Severity Published in the American Association of Poison Control Centers&rsquo; Annual Reports from 1983-2007,&rdquo;",
"      <i>",
"       Clin Toxicol (Phila)",
"      </i>",
"      , 2010, 48(1):72-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/57/34708/abstract-text/20070180/pubmed\" id=\"20070180\" target=\"_blank\">",
"        20070180",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      World Health Organization, \"Guidelines for the Clinical Management of Snake Bites in the South-East Asia Region,\" 2005, World Health Organization, Geneva. Available at file://www.searo.who.int/LinkFiles/SDE_mgmt_snake-bite.pdf",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9766 Version 32.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-83.177.194.223-77399545CD-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_57_34708=[""].join("\n");
var outline_f33_57_34708=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265238\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136142\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136133\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136139\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136134\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673205\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15673206\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136122\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136110\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136124\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136123\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136140\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136126\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136114\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298766\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136117\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13265239\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13359938\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F136113\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9766\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9766|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?22/7/22643?source=related_link\">",
"      North American coral snake (Micrurus fulvius) antivenom: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_57_34709="Ioversol: Drug information";
var content_f33_57_34709=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ioversol: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/21/11604?source=see_link\">",
"    see \"Ioversol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F9520848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F184022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Optiray&reg; 240;",
"     </li>",
"     <li>",
"      Optiray&reg; 300;",
"     </li>",
"     <li>",
"      Optiray&reg; 320;",
"     </li>",
"     <li>",
"      Optiray&reg; 350",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F15793706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Optiray&reg; 240;",
"     </li>",
"     <li>",
"      Optiray&reg; 300;",
"     </li>",
"     <li>",
"      Optiray&reg; 320;",
"     </li>",
"     <li>",
"      Optiray&reg; 350",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F184025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Iodinated Contrast Media;",
"     </li>",
"     <li>",
"      Radiological/Contrast Media (Nonionic, Low Osmolality)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9524681\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dosing is based on numerous variables including: Type of examination, route of administration, patient age/weight and product; consult specific product information for detailed dosing information.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9524680\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F9524682\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15962287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Use caution in severe impairment and in setting of combined renal and hepatic disease.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15962288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling. Use caution in patients with combined hepatic and renal disease.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F184013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Optiray&reg; 240: 51% (50 mL, 100 mL, 125 mL, 150 mL, 200 mL) [contains edetate calcium disodium; provides organically-bound iodine 240 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Optiray&reg; 300: 64% (50 mL, 100 mL, 125 mL [DSC], 150 mL, 200 mL, 500 mL) [contains edetate calcium disodium; provides organically-bound iodine 300 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Optiray&reg; 320: 68% (20 mL, 30 mL, 50 mL, 75 mL, 100 mL, 125 mL, 150 mL, 200 mL) [contains edetate calcium disodium; provides organically-bound iodine 320 mg/mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Optiray&reg; 350: 74% (30 mL [DSC], 50 mL, 75 mL, 100 mL, 125 mL, 150 mL, 200 mL, 250 mL, 500 mL) [contains edetate calcium disodium; provides organically-bound iodine 350 mg/mL]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F184009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9524683\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Withdrawal of contrast agents from container should be completed with aseptic technique. Intravenous doses should be at body temperature prior to administration.  In angiography, use meticulous intravascular administration technique to minimize thrombotic events including use of plastic syringes, frequent catheter flushing, and close attention to catheter and guidewire manipulation.",
"     <b>",
"      Not for intrathecal use.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F184014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Arteriography, angiography, angiocardiography, ventriculography, excretory urography, and venography procedures; contrast enhanced tomographic imaging",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F5174553\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9521837\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &gt;10%: Central nervous system: Headache (16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cardiovascular: Angina pectoris (3%), flushing (2%), bradycardia (1%), hypotension (1%), arrhythmias, hypertension (in patients with phenochromocytoma after intra-arterial injection), myocardial ischemia, tachycardia, venous thrombosis, ventricular fibrillation, ventricular tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Central nervous system: Hot flashes (3%), chills, fever, transient ischemic attack",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Dermatologic: Hives (1%), pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Gastrointestinal: Nausea (7%), vomiting (4%), anorexia, taste alterations",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Genitourinary: Urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Local: Burning sensation (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Neuromuscular &amp; skeletal: Back pain (2%), leg pain (1%), neck pain (1%), back spasm, paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Ocular: Vision abnormalities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Renal: Contrast-associated nephropathy, creatinine increased, renal dysfunction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Respiratory: Bronchospasm, cough, dyspnea, pulmonary edema, rhinitis, sneezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Miscellaneous: Diaphoresis, hypersensitivity reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     &lt;1%: Abdominal cramps, amnesia (temporary), anaphylactoid reaction, apnea, arterial spasms, asthma, ataxia, cardiopulmonary arrest, chest pain/tightness, cold extremities, coma, confusion, conjunctivitis, cough increased, cortical blindness (temporary), diarrhea, dizziness, emotional stress, facial edema, fatigue, hallucinations, heartburn, hematuria, injection site pain, involuntary leg movements, irritability, lacrimation, laryngeal edema, leg cramps, lightheadedness, malaise, muscle spasm, neuralgia, numbness, paralysis, involuntary leg movements, sciatica, seizure, syncope, thyrotoxicosis exacerbation, tinnitus, tremor, weakness",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F184016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9520849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Allergic reactions: Use extreme caution with history of previous reaction to contrast dye, iodine-based contrast media or patients with a known clinical hypersensitivity (eg, bronchial asthma, hay fever or food allergies). Premedication with antihistamines or corticosteroids can be considered to reduce incidence and severity of reaction. Severe, potentially life-threatening reactions and delayed reactions may occur. Monitor closely after injection.",
"     <b>",
"      [U.S. Boxed Warning]: Must be administered in a setting where staff is familiar with the recognition and treatment of allergic reactions.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Contrast-associated nephropathy:",
"     <b>",
"      [U.S. Boxed Warnings]: Use caution in patients with significant underlying renal impairment, concurrent renal and hepatic impairment, especially when large doses are required.",
"     </b>",
"     Patients should be well hydrated before and after examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neurologic impairment:",
"     <b>",
"      [U.S. Boxed Warning]: Serious neurologic events including paralysis can occur following cerebral arteriography, selective spinal arteriography, and arteriography of blood vessels supplying the spinal cord. Cause and effect has not been established as underlying disease may contribute; Avoid arterial injection of contrast medium after vasopressor administration.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizures: Caution in patients with history of epilepsy; focal and generalized motor seizures have been reported when higher than recommended doses used; antiepileptic therapy should be continued. Prophylactic anticonvulsant therapy should be considered in patients requiring a concentrated solution or large bolus of contrast media. CNS-acting agents, primarily those which lower seizure threshold (eg, phenothiazines, MAO inhibitors, tricyclic antidepressants, SSRIs), should be discontinued 24-72 hours prior to intrathecal use and not resumed for 24 hours post procedure (ACR, 2008).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Thromboembolic events:",
"     <b>",
"      [U.S. Boxed Warning]: Serious, rarely fatal, thromboembolic events causing myocardial infarction (MI) and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Clotting may occur when blood remains in contact with syringes containing nonionic contrast media. Use meticulous intravascular administration techniques during angiographic procedures.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease:  Use caution in severe cardiovascular disease and heart failure; transitory increase in circulatory osmotic load could occur.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Chronic alcoholism: Use caution in patients with alcoholism taking metformin.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatorenal insufficiency:",
"     <b>",
"      [U.S. Boxed Warning]: Use caution in hepatorenal insufficiency.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperthyroidism:",
"     <b>",
"      [U.S. Boxed Warning]: Reports of thyroid storm following administration of iodinated contrast media have been reported in patients with hyperthyroidism or with an autonomously functioning thyroid nodule.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Multiple myeloma:",
"     <b>",
"      [U.S. Boxed Warning]: Use with caution in multiple myeloma; use of intravascular contrast agents may lead to renal dysfunction, especially with concurrent dehydration.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pheochromocytoma:",
"     <b>",
"      [U.S Boxed Warning]: Use extreme caution in patients with pheochromocytoma. Analyze the risk versus benefit of the procedure; use the smallest amount of contrast medium and closely monitor blood pressure throughout the study duration. Therapy for treatment of hypertensive crisis should be readily available.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal disease:  Use caution in renal disease.  May be associated with deterioration of renal function and/or increases in serum creatinine, particularly in diabetics, elderly, advanced vascular disease, and those who are dehydrated.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sickle cell disease:",
"     <b>",
"      [U.S. Boxed Warning]: Use caution in homozygous sickle cell patients; administration of contrast media may result in sickling.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate administration:",
"     <b>",
"      [U.S. Boxed Warning]: Inadvertent administration of iodinated contrast media that is not indicated for intrathecal use has resulted in serious adverse events.",
"     </b>",
"     Precautions should be taken to ensure ioversol is not administered intrathecally.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299535\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6221113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Contrast Media (Non-ionic) may enhance the potential for allergic or hypersensitivity reactions to Aldesleukin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MetFORMIN: Iodinated Contrast Agents may enhance the adverse/toxic effect of MetFORMIN. Renal dysfunction that may be caused by iodinated contrast agents may lead to metformin-associated lactic acidosis.  Management: Withhold metformin from all patients receiving intravascular iodinated contrast agents prior to or at the time of the procedure and for at least 48 hrs thereafter.  Document adequate renal function before restarting metformin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F184011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F184018\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Fetal harm was not observed in animal studies. In general, iodinated contrast media agents are avoided during pregnancy unless essential for diagnosis.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F184023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F184019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A very small percentage of iodinated contrast medium is excreted into breast milk. The expected dose absorbed by the infant from breast milk is &lt;0.01% (&lt;1% of the dose an infant would receive if undergoing an imaging study). American College of Radiology (ACR) suggests that it is safe for mother and infant to continue breast-feeding after mother receives a contrast medium (ACR, 2008). If mother remains concerned, bottle feedings of previously expressed breast milk are recommended for 24 hours after contract administration.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Optiray 160 Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     34% (50 mL): $39.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Optiray 240 Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     51% (100 mL): $83.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Optiray 300 Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     64% (150 mL): $135.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Optiray 320 Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     68% (50 mL): $57.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Optiray 350 Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     74% (150 mL): $159.60",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F6038661\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Optiject (FR);",
"     </li>",
"     <li>",
"      Optiray (AR, AT, AU, BE, BG, CH, CO, CZ, DK, GB, GR, HN, IE, IT, KP, NL, NO, NZ, PE, PT, PY, SE, SG)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9524674\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Opacification of vessels and anatomical structures in the path of flow of the contrast media which allows for radiographic visualization.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9524676\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life elimination: ~2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Excretion: Urine: &gt;95% eliminated unchanged in urine 24 hours postadministration; delayed with renal impairment",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Committee on Obstetric Practice, &ldquo;ACOG Committee Opinion. Guidelines for Diagnostic Imaging During Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2004, 104(3):647-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/57/34709/abstract-text/15339791/pubmed\" id=\"15339791\" target=\"_blank\">",
"        15339791",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Radiology, &ldquo;Manual on Contrast Media, Version 7.0&rdquo;, 2010. Available at file://gm.acr.org/SecondaryMainMenuCategories/quality_safety/contrast_manual.aspx",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Radiology, &ldquo;Practice Guideline for the Performance of Myelography and Cisternography,&rdquo; Available at  file://www.acr.org/SecondaryMainMenuCategories/quality_safety/guidelines/dx/head-neck/myelography.aspx",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Jneid H, Anderson JL, Wright RS, et al, &ldquo;2012 ACCF/AHA Focused Update of the Guideline for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline and Replacing the 2011 Focused Update): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2012, 126(7):875-910.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/57/34709/abstract-text/22800849/pubmed\" id=\"22800849\" target=\"_blank\">",
"        22800849",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Klein LW, Sheldon MW, Brinker J, et al, &ldquo;The Use of Radiographic Contrast Media During PCI: A Focused Review: A Position Statement of the Society of Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Catheter Cardiovasc Interv",
"      </i>",
"      , 2009, 74(4):728-46.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/57/34709/abstract-text/19830793/pubmed\" id=\"19830793\" target=\"_blank\">",
"        19830793",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Laskey WK, Jenkins C, Selzer F, et al, &ldquo;Volume-to-Creatinine Clearance Ratio: A Pharmacokinetically Based Risk Factor for Prediction of Early Creatinine Increase After Percutaneous Coronary Intervention,&rdquo;",
"      <i>",
"       J Am Coll Cardiol",
"      </i>",
"      , 2007, 50(7):584-90.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/57/34709/abstract-text/17692741/pubmed\" id=\"17692741\" target=\"_blank\">",
"        17692741",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine GN, Bates ER, Blankenship JC, et al, &ldquo;2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,&rdquo;",
"      <i>",
"       Circulation",
"      </i>",
"      , 2011, 124(23):e574-651.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/57/34709/abstract-text/22064601/pubmed\" id=\"22064601\" target=\"_blank\">",
"        22064601",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8964 Version 39.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-180.241.123.62-6A9128D992-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_57_34709=[""].join("\n");
var outline_f33_57_34709=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9520848\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184022\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15793706\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184025\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524681\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524680\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524682\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962287\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15962288\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184013\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184009\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524683\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184014\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5174553\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9521837\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184016\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9520849\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299535\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6221113\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184011\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184018\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184023\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F184019\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323209\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6038661\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524674\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9524676\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8964\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8964|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/21/11604?source=related_link\">",
"      Ioversol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_57_34710="Ulcerative lesion secondary to bacillary angiomatosis";
var content_f33_57_34710=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F82761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F82761&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Ulcerative lesion secondary to bacillary angiomatosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_57_34710=[""].join("\n");
var outline_f33_57_34710=null;
var title_f33_57_34711="Potassium chloride: Drug information";
var content_f33_57_34711=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Potassium chloride: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/8/14469?source=see_link\">",
"    see \"Potassium chloride: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/17/11542?source=see_link\">",
"    see \"Potassium chloride: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F211820\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      K-Tab&reg;;",
"     </li>",
"     <li>",
"      Kaon-CL&reg; 10;",
"     </li>",
"     <li>",
"      Klor-Con&reg;;",
"     </li>",
"     <li>",
"      Klor-Con&reg; 10;",
"     </li>",
"     <li>",
"      Klor-Con&reg; 8;",
"     </li>",
"     <li>",
"      Klor-Con&reg; M10;",
"     </li>",
"     <li>",
"      Klor-Con&reg; M15;",
"     </li>",
"     <li>",
"      Klor-Con&reg; M20;",
"     </li>",
"     <li>",
"      Klor-Con&reg;/25;",
"     </li>",
"     <li>",
"      microK&reg;;",
"     </li>",
"     <li>",
"      microK&reg; 10",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F211821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-K&reg;;",
"     </li>",
"     <li>",
"      K-10&reg;;",
"     </li>",
"     <li>",
"      K-Dur&reg;;",
"     </li>",
"     <li>",
"      Micro-K Extencaps&reg;;",
"     </li>",
"     <li>",
"      Roychlor&reg;;",
"     </li>",
"     <li>",
"      Slo-Pot;",
"     </li>",
"     <li>",
"      Slow-K&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F211838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Electrolyte Supplement, Oral;",
"     </li>",
"     <li>",
"      Electrolyte Supplement, Parenteral",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F211823\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. doses should be incorporated into the patient's maintenance I.V. fluids; intermittent I.V. potassium administration should be reserved for severe depletion situations in patients undergoing ECG monitoring. Doses expressed as mEq of potassium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Normal daily requirements:",
"     </b>",
"     <i>",
"      Oral, I.V.:",
"     </i>",
"     40-80 mEq/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of hypokalemia:",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     20-40 mEq/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of hypokalemia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Asymptomatic, mild hypokalemia: Usual dosage range: 40-100 mEq/day divided in 2-5 doses; generally recommended to limit doses to 20-25 mEq/dose to avoid GI discomfort.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild-to-moderate hypokalemia: Some clinicians may administer up to 120-240 mEq/day divided in 3-4 doses; generally recommended to limit doses to 40-60 mEq/dose. If deficits are severe or ongoing losses are great, I.V. route should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V. intermittent infusion:",
"     </i>",
"     Peripheral or central line: &le;10 mEq/hour; repeat as needed based on frequently obtained lab values; central line infusion and continuous ECG monitoring highly recommended for infusions &gt;10 mEq/hour.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Potassium dosage/rate of infusion general guidelines (per product labeling):",
"     <b>",
"      Note:",
"     </b>",
"     High variability exists in dosing/infusion rate recommendations; therapy guided by patient condition and specific institutional guidelines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Serum potassium &gt;2.5-3.5 mEq/L: Maximum infusion rate: 10 mEq/hour; maximum concentration: 40 mEq/L; maximum 24-hour dose: 200 mEq",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Serum potassium &lt;2.5 mEq/L or symptomatic hypokalemia (excluding emergency treatment of cardiac arrest): Maximum infusion rate (central line only): 40 mEq/hour  in presence of  continuous  ECG monitoring and frequent lab monitoring; In selected situations, patients may require up to 400 mEq/24 hours.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F211833\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/17/11542?source=see_link\">",
"      see \"Potassium chloride: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.V. doses should be incorporated into the patient's maintenance I.V. fluids; intermittent I.V. potassium administration should be reserved for severe depletion situations in patients undergoing ECG monitoring. Doses expressed as mEq of potassium.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Normal daily requirements:",
"     </b>",
"     <i>",
"      Oral, I.V.:",
"     </i>",
"     1-2 mEq/kg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prevention of hypokalemia:",
"     </b>",
"     <i>",
"      Oral:",
"     </i>",
"     1-2 mEq/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of hypokalemia:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     1-2 mEq/kg initially, then as needed based on frequently obtained lab values. If deficits are severe or ongoing losses are great, I.V. route should be considered.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      I.V. intermittent infusion:",
"     </i>",
"     0.5-1 mEq/kg/dose (maximum dose: 40 mEq). If infusion  exceeds 0.5 mEq/kg/hour, physician should be at bedside and patient should have continuous ECG monitoring; repeat as needed based on frequently obtained lab values.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F211824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F211804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, extended release, microencapsulated, oral: 8 mEq, 10 mEq",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     microK&reg;: 8 mEq [600 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     microK&reg; 10: 10 mEq [750 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in 1/2 NS: 20 mEq (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     1/2 NS: 10 mEq (500 mL, 1000 mL); 20 mEq (1000 mL); 30 mEq (1000 mL); 40 mEq (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     1/3 NS: 20 mEq (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     1/4 NS: 5 mEq (250 mL); 10 mEq (500 mL); 20 mEq (1000 mL); 40 mEq (1000 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     LR: 20 mEq (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     NS: 20 mEq (1000 mL); 40 mEq (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W: 20 mEq (1000 mL); 40 mEq (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS: 20 mEq (1000 mL); 40 mEq (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in water for injection [highly concentrated]: 10 mEq (50 mL, 100 mL); 20 mEq (50 mL, 100 mL); 30 mEq (100 mL); 40 mEq (100 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate]: 2 mEq/mL (5 mL, 10 mL, 15 mL, 20 mL, 30 mL, 250 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [concentrate, preservative free]: 2 mEq/mL (5 mL, 10 mL, 15 mL [DSC], 20 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Powder for solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Klor-Con&reg;: 20 mEq/packet (30s, 100s) [sugar free; fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Klor-Con&reg;/25: 25 mEq/packet (30s, 100s) [sugar free; fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 20 mEq/15 mL (15 mL, 30 mL, 473 mL, 480 mL); 40 mEq/15 mL (15 mL, 473 mL, 480 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral: 10 mEq",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, microencapsulated, oral: 8 mEq, 10 mEq, 20 mEq",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Klor-Con&reg; M10: 10 mEq [750 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Klor-Con&reg; M15: 15 mEq [scored; 1125 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Klor-Con&reg; M20: 20 mEq [scored; 1500 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, wax matrix, oral: 8 mEq, 10 mEq",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     K-Tab&reg;: 10 mEq [750 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Kaon-CL&reg; 10: 10 mEq [750 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Klor-Con&reg; 8: 8 mEq [600 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Klor-Con&reg; 10: 10 mEq [750 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F211789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes powder for solution",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F211806\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: Potassium must be diluted prior to parenteral administration. Do not administer I.V. push. In general, the dose, concentration of infusion and rate of administration may be dependent on patient condition and specific institution policy. Some clinicians recommend that the maximum concentration for peripheral infusion is 10 mEq/100 mL and maximum rate of administration for peripheral infusion is 10 mEq/hour. ECG monitoring is recommended for peripheral or central infusions &gt;10 mEq/hour in adults. Concentrations and rates of infusion may be greater with central line administration. Some clinicians recommend that the maximum concentration for central infusion is 20-40 mEq/100 mL and maximum rate of administration for central infusion is 40 mEq/hour.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Oral dosage forms should be taken with meals and a full glass of water or other liquid to minimize the risk of GI irritation. Prescribing information for the various oral preparations recommend that no more than 20 mEq or 25 mEq should be given as single dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Capsule: MicroK&reg;: Swallow whole, do not chew. Capsules may also be opened and contents sprinkled on a spoonful of applesauce or pudding and should be swallowed immediately without chewing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Powder: Klor-Con&reg;: Dissolve one packet in 4-5 ounces of water or other beverage prior to administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tablet:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     K-Tab&reg;, Kaon-Cl&reg;, Klor-Con&reg;: Swallow tablets whole; do not crush, chew, or suck on tablet.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Klor-Con&reg; M: Swallow tablets whole; do not crush, chew, or suck on tablet. Tablet may also be broken in half and each half swallowed separately; the whole tablet may be dissolved in ~4 ounces of water (allow ~2 minutes to dissolve, stir well and drink immediately)",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F211844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, D",
"     <sub>",
"      20",
"     </sub>",
"     W, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS;",
"     <b>",
"      variable compatibility (consult detailed reference)",
"     </b>",
"     in fat emulsion 10%, mannitol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acyclovir, allopurinol, amifostine, aminophylline, amiodarone, ampicillin, anidulafungin, atropine, aztreonam, bivalirudin, calcium gluconate, caspofungin, chlorpromazine, ciprofloxacin, cisatracurium, cladribine, clonidine, cyanocobalamin, dexamethasone sodium phosphate, dexmedetomidine, digoxin, diltiazem, diphenhydramine, dobutamine, docetaxel, dopamine, doripenem, doxorubicin liposome, droperidol, drotrecogin alfa, edrophonium, enalaprilat, epinephrine, ertapenem, esmolol, estrogens (conjugated), ethacrynate, etoposide phosphate, famotidine, fenoldopam, fentanyl, filgrastim, fludarabine, fluorouracil, furosemide, gallium nitrate, gemcitabine, gentamicin, gold sodium thiosulfate, granisetron, heparin, hetastarch in lactate electrolyte injection (Hextend&reg;), hydralazine, idarubicin, inamrinone, indomethacin, insulin (regular), isoproterenol, kanamycin, labetalol, levofloxacin, lidocaine, linezolid, lorazepam, magnesium sulfate, melphalan, meperidine, methylergonovine, micafungin, milrinone, minocycline, morphine, neostigmine, nicardipine, nitroglycerin, nitroprusside, norepinephrine, ondansetron, oxacillin, oxaliplatin, oxytocin, paclitaxel, palonosetron, pancuronium, pantoprazole, pemetrexed, penicillin G potassium, pentazocine, phenylephrine, phytonadione, piperacillin/tazobactam, procainamide, prochlorperazine edisylate, propofol, propranolol, pyridostigmine, quinupristin/dalfopristin, remifentanil, sargramostim, scopolamine, sodium bicarbonate, succinylcholine, tacrolimus, telavancin, teniposide, terbutaline, theophylline, thiotepa, tigecycline, tirofiban, trimethobenzamide, vasopressin, vinorelbine, warfarin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amphotericin B cholesteryl sulfate complex, azithromycin, diazepam, ergotamine, phenytoin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Aldesleukin, meropenem, methylprednisolone sodium succinate, midazolam, promethazine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Hydromorphone, pantoprazole, thiamine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Dimenhydrinate.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F211805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment or prevention of hypokalemia",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F211846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Kaon-Cl-10&reg; may be confused with kaolin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       KCl may be confused with HCl",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Klor-Con&reg; may be confused with Klaron&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       microK&reg; may be confused with Macrobid&reg;, Micronase",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication (I.V. formulation) among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Per JCAHO recommendations, concentrated electrolyte solutions should not be available in patient care areas.",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Consider special storage requirements for intravenous potassium salts; I.V. potassium salts have been administered IVP in error, leading to fatal outcomes.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F211836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hyperkalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain/discomfort, diarrhea, flatulence, GI bleeding (oral), GI obstruction (oral), GI perforation (oral), nausea, vomiting",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F211809\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to any component of the formulation; hyperkalemia. In addition, solid oral dosage forms are contraindicated in patients in whom there is a structural, pathological, and/or pharmacologic cause for delay or arrest in passage through the GI tract.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F211793\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hyperkalemia: Close monitoring of serum potassium concentrations is needed to avoid hyperkalemia; severe hyperkalemia may lead to muscle weakness/paralysis and cardiac conduction abnormalities (eg, heart block, ventricular arrhythmias, asystole).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acid/base disorders: Use with caution in patients with acid/base alterations; changes in serum potassium concentrations can occur during acid/base correction, monitor closely.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with cardiovascular disease (eg, heart failure, cardiac arrhythmias); patients may be more susceptible to life-threatening cardiac effects associated with hyper/hypokalemia.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potassium-altering conditions/disorders: Use with caution in patients with disorders or conditions likely to contribute to altered serum potassium and hyperkalemia (eg, untreated Addison's disease, heat cramps, severe tissue breakdown from trauma or burns).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; monitor serum potassium concentrations closely. Contraindicated with severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Digitalis: Use with caution in digitalized patients; may be more susceptible to potentially life-threatening cardiac effects with rapid changes in serum potassium concentrations.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Potassium-altering therapies: Use with caution in patients receiving concomitant medications or therapies that increase potassium (eg, ACEI, potassium-sparing diuretics, potassium containing salt substitutes).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Oral formulations: May cause GI upset (eg, nausea, vomiting, diarrhea, abdominal pain, discomfort) and lead to GI ulceration, bleeding, perforation, and/or obstruction. Oral liquid preparations (not solid) should be used in patients with esophageal compression or delayed gastric emptying.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Parenteral administration: Use extreme caution with parenteral administration and monitor serum potassium concentrations closely. Evaluate renal function, cardiac and fluid status, and any factors contributing to altered potassium concentrations (eg, acidosis, alkalosis) prior to therapy. Do",
"     <b>",
"      NOT",
"     </b>",
"     administer undiluted or I.V. push; inappropriate parenteral administration may be fatal. Always administer potassium further diluted; refer to appropriate dilution and administration rate recommendations. Pain and phlebitis may occur during parenteral infusion requiring a decrease in infusion rate or potassium concentration. Avoid administering potassium diluted in dextrose solutions during initial therapy; potential for transient decreases in serum potassium due to intracellular shift of potassium from dextrose-stimulated insulin release.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F211798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ACE Inhibitors: Potassium Salts may enhance the hyperkalemic effect of ACE Inhibitors.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Angiotensin II Receptor Blockers: Potassium Salts may enhance the hyperkalemic effect of Angiotensin II Receptor Blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergic Agents: May enhance the ulcerogenic effect of Potassium Chloride. Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: May enhance the hyperkalemic effect of Potassium Salts. Management: This combination is contraindicated in patients receiving eplerenone for treatment of hypertension.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Glycopyrrolate: May enhance the adverse/toxic effect of Potassium Chloride. This is specific to solid oral dosage forms of potassium chloride. Management: Concurrent use of solid oral dosage forms of potassium chloride are contraindicated with glycopyrrolate.  Consider using a non-solid oral dosage form or another alternative therapy as appropriate.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium-Sparing Diuretics: Potassium Salts may enhance the hyperkalemic effect of Potassium-Sparing Diuretics.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F211800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F5186460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reproduction studies have not been conducted. Potassium requirements are the same in pregnant and nonpregnant women. Adverse events have not been observed following use of potassium supplements in healthy women with normal pregnancies. Use caution in pregnant women with other medical conditions (eg, pre-eclampsia; may be more likely to develop hyperkalemia) (IOM, 2004). Potassium supplementation (that does not cause maternal hyperkalemia) would not be expected to cause adverse fetal events.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F5186462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F5186463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potassium is excreted into breast milk (IOM, 2004). The normal content of potassium in human milk is ~13 mEq/L. Supplementation (that does not cause maternal hyperkalemia) would not be expected to affect normal concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F211812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with plenty of fluid to decrease stomach irritation and discomfort. Some dietary sources of potassium include leafy green vegetables (eg, spinach, cabbage), tomatoes, cucumbers, zucchini, fruits (eg, apples, oranges, and bananas), root vegetables (eg, carrots, radishes), beans, and peas.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F211811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, controlled release",
"     </b>",
"     (Micro-K Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mEq (100): $100.34",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mEq (100): $105.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsule, controlled release",
"     </b>",
"     (Potassium Chloride ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mEq (100): $93.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mEq (100): $99.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Potassium Chloride Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 MEQ/15ML (10%) (473 mL): $11.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 MEQ/15ML (20%) (473 mL): $19.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (K-Lor Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mEq (30): $37.43",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pack",
"     </b>",
"     (Klor-Con Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mEq (30): $58.21",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mEq (30): $69.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (KCl in Dextrose-NaCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mEq/L 5-0.45%-% (1000 mL): $2.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mEq/L 5-0.2%-% (1000 mL): $2.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mEq/L 5-0.225%-% (500 mL): $3.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mEq/L 5-0.33%-% (500 mL): $2.97",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mEq/L 5-0.45%-% (1000 mL): $2.15",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mEq/L 5-0.9%-% (1000 mL): $3.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mEq/L 5-0.45%-% (1000 mL): $3.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mEq/L 5-0.45%-% (1000 mL): $2.90",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mEq/L 5-0.9%-% (1000 mL): $3.77",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Potassium Chloride in Dextrose Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mEq/L 5% (1000 mL): $2.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mEq/L 5% (1000 mL): $2.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Potassium Chloride in NaCl Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mEq/L 0.45% (1000 mL): $3.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mEq/L 0.9% (1000 mL): $3.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mEq/L 0.9% (1000 mL): $3.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Potassium Chloride Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     2 mEq/mL (20 mL): $1.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mEq/100 mL (100 mL): $3.12",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mEq/50 mL (50 mL): $3.02",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mEq/100 mL (100 mL): $3.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mEq/50 mL (50 mL): $3.22",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mEq/100 mL (100 mL): $3.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     40 mEq/100 mL (100 mL): $3.13",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (K-Tabs Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mEq (100): $87.26",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Klor-Con 10 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mEq (100): $56.46",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Klor-Con M10 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mEq (100): $59.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Klor-Con M15 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mEq (100): $61.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Klor-Con M20 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mEq (100): $62.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Klor-Con Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mEq (100): $53.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Potassium Chloride Crys ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mEq (100): $59.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mEq (100): $62.73",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, controlled release",
"     </b>",
"     (Potassium Chloride ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8 mEq (1000): $536.36",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mEq (1000): $555.87",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F211802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Serum potassium, chloride, magnesium (to facilitate potassium repletion), cardiac monitor (if intermittent infusion or potassium infusion rates 0.5 mEq/kg/hour in children or &gt;10 mEq/hour in adults); to assess adequate replacement, repeat serum potassium level 2-4 hours after dose",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F13203026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Reference ranges may vary depending on the laboratory",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum potassium: 3.5-5.2 mEq/L",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F2869402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acronitol (GR);",
"     </li>",
"     <li>",
"      Addi-K (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, MY, NE, NG, SC, SD, SL, SN, TH, TN, TW, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Apo-K (MY);",
"     </li>",
"     <li>",
"      Beacon K SR (MY);",
"     </li>",
"     <li>",
"      Chloropotassuril (BE);",
"     </li>",
"     <li>",
"      Chlorvescent (NZ);",
"     </li>",
"     <li>",
"      Corpotasin (MX);",
"     </li>",
"     <li>",
"      Diffu-K (FR);",
"     </li>",
"     <li>",
"      Durekal (FI);",
"     </li>",
"     <li>",
"      Duro-K 600 (AU);",
"     </li>",
"     <li>",
"      Enpott (TH);",
"     </li>",
"     <li>",
"      K-Contin (BF, BJ, CI, ET, GH, GM, GN, KE, KP, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      K-Dur (MX);",
"     </li>",
"     <li>",
"      K-Tab (PK);",
"     </li>",
"     <li>",
"      Kaleorid (DK, FR, NO, SE);",
"     </li>",
"     <li>",
"      Kalinor-Retard P (DE);",
"     </li>",
"     <li>",
"      Kalinorm (FI);",
"     </li>",
"     <li>",
"      Kalipoz (PL);",
"     </li>",
"     <li>",
"      Kalium (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, NL, PH, SC, SD, SL, SN, TN, TZ, UG, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Kalium-Durettes (NL);",
"     </li>",
"     <li>",
"      Kalium-R (CH, HN);",
"     </li>",
"     <li>",
"      Kay-Cee-L (GB, IE);",
"     </li>",
"     <li>",
"      KCL Retard (AE, AT, BH, CY, CZ, EG, GR, HN, IQ, IR, IT, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Kelefusin (MX);",
"     </li>",
"     <li>",
"      Keylyte (IN);",
"     </li>",
"     <li>",
"      KSR (HK, ID);",
"     </li>",
"     <li>",
"      Lento-Kalium (IT);",
"     </li>",
"     <li>",
"      Micro-Kalium Retard (AT);",
"     </li>",
"     <li>",
"      Nu-K (IE);",
"     </li>",
"     <li>",
"      Perennum (PY);",
"     </li>",
"     <li>",
"      Rekawan (DE);",
"     </li>",
"     <li>",
"      Rekawan Retard (AT);",
"     </li>",
"     <li>",
"      Sando-K (GB);",
"     </li>",
"     <li>",
"      Slow-K (AE, AR, AU, BB, BF, BH, BJ, BM, BS, BZ, CI, CN, CY, EG, ET, GB, GH, GM, GN, GY, HK, IL, IQ, IR, JM, JO, KE, KW, LB, LR, LY, MA, ML, MR, MU, MW, MY, NE, NG, NL, NZ, OM, PR, QA, SA, SC, SD, SL, SN, SR, SY, TN, TT, TW, TZ, UG, UY, YE, ZA, ZM, ZW);",
"     </li>",
"     <li>",
"      Span-K (AU, HK, MY, NZ)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F211792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potassium is the major cation of intracellular fluid and is essential for the conduction of nerve impulses in heart, brain, and skeletal muscle; contraction of cardiac, skeletal and smooth muscles; maintenance of normal renal function, acid-base balance, carbohydrate metabolism, and gastric secretion",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F211808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Well absorbed from upper GI tract",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Enters cells via active transport from extracellular fluid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine; skin and feces (small amounts); most intestinal potassium reabsorbed",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Alfonzo AV, Isles C, Geddes C, et al, &ldquo;Potassium Disorders - Clinical Spectrum and Emergency Management,&rdquo;",
"      <i>",
"       Resuscitation",
"      </i>",
"      , 2006, 70(1):10-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/57/34711/abstract-text/16600469/pubmed\" id=\"16600469\" target=\"_blank\">",
"        16600469",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      ASPEN Board of Directors and the Clinical Guidelines Task Force, &ldquo;Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients,&rdquo;",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2002, 26(1 Suppl):22-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/57/34711/abstract-text/11841046/pubmed\" id=\"11841046\" target=\"_blank\">",
"        11841046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      ASPEN Board of Directors and the Clinical Guidelines Task Force, &ldquo;Guidelines for the Use of Parenteral and Enteral Nutrition in Adult and Pediatric Patients,&rdquo;",
"      <i>",
"       JPEN J Parenter Enteral Nutr",
"      </i>",
"      , 2002, 26(1 Suppl):25-32.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/57/34711/abstract-text/11841046/pubmed\" id=\"11841046\" target=\"_blank\">",
"        11841046",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hamill RJ, Robinson LM, Wexler HR, et al, &ldquo;Efficacy and Safety of Potassium Infusion Therapy in Hypokalemic Critically Ill Patients,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1991, 19(5):694-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/57/34711/abstract-text/2026032/pubmed\" id=\"2026032\" target=\"_blank\">",
"        2026032",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of Medicine),",
"      <i>",
"       Dietary Reference Intakes for Water, Potassium, Sodium, Chloride, and Sulfate",
"      </i>",
"      , Washington, DC: National Academy Press, 2004.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Khilnani P, &ldquo;Electrolyte Abnormalities in Critically Ill Children,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1992, 20(2):241-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/57/34711/abstract-text/1737458/pubmed\" id=\"1737458\" target=\"_blank\">",
"        1737458",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Joint Commission on Accreditation of Healthcare Organizations, &ldquo;2005 National Patient Safety Goals,&rdquo; available at file://www.jointcommission.org/PatientSafety/NationalPatientSafetyGoals/05_npsgs.htm",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Weiss-Guillet EM, Takala J, and Jakob SM, &ldquo;Diagnosis and Management of Electrolyte Emergencies,&rdquo;",
"      <i>",
"       Best Pract Res Clin Endocrinol Metab",
"      </i>",
"      , 2003, 17(4):623-51.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?33/57/34711/abstract-text/14687593/pubmed\" id=\"14687593\" target=\"_blank\">",
"        14687593",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9795 Version 41.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-194.187.108.93-9EF4B3CCD6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_57_34711=[""].join("\n");
var outline_f33_57_34711=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211820\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211821\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211838\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211823\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211833\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211824\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211804\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211789\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211806\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211844\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211805\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211846\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211836\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211809\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211793\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299917\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211798\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211800\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5186460\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5186462\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5186463\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211812\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211811\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211802\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13203026\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2869402\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211792\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F211808\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9795\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9795|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?14/8/14469?source=related_link\">",
"      Potassium chloride: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?11/17/11542?source=related_link\">",
"      Potassium chloride: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_57_34712="Antimicrobial therapy of prosthetic valve endocarditis";
var content_f33_57_34712=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Antimicrobial therapy of prosthetic valve endocarditis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/57/34712/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/57/34712/contributors\">",
"     Adolf W Karchmer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/57/34712/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/57/34712/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/57/34712/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/57/34712/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/57/34712/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection of a prosthetic heart valve can be difficult to diagnose and manage. Optimal treatment of prosthetic valve endocarditis (PVE) requires:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Identification of the causative microorganism.",
"     </li>",
"     <li>",
"      Selection of a bactericidal antimicrobial regimen of proven efficacy.",
"     </li>",
"     <li>",
"      A clear understanding of the intracardiac pathology and attendant complications of PVE.",
"     </li>",
"     <li>",
"      Surgical intervention, especially when infection has extended beyond the valve to contiguous cardiac tissue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The antimicrobial therapy of prosthetic valve endocarditis will be reviewed here. The pathogenesis, microbiology, pathology, clinical features, diagnosis, prevention, and surgical management of PVE are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/40/2697?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/32/3591?source=see_link\">",
"     \"Surgery for prosthetic valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of prosthetic valve endocarditis (PVE) with antimicrobial agents alone frequently fails, and invasive infection with subsequent valve dysfunction often arises before or during therapy. Thus, all treatment for PVE should be initiated in the hospital, preferably in an institution where cardiac surgery is available. Patients should remain hospitalized until fever resolves and it is clear that surgery can be safely avoided.",
"   </p>",
"   <p>",
"    It is essential to isolate the causative organism in patients with suspected PVE. For patients who are hemodynamically stable with an indolent clinical course, antibiotic therapy should be delayed pending the blood culture results. This delay allows additional blood cultures to be obtained without the confounding effect of antibiotics, which is particularly important for patients who have received recent antimicrobial agents and whose initial blood cultures may be negative.",
"   </p>",
"   <p>",
"    However, patients presenting with hemodynamic instability or acute disease should receive empiric antibiotics promptly after three sets of blood cultures have been obtained. Empiric antibiotic therapy with three agents should be initiated:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , and either",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    or a carbapenem. Subsequent therapy should be adjusted based on culture results; if cultures remain negative, therapy as outlined for culture negative PVE should be used. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Culture-negative'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Antimicrobial treatment regimens for PVE are based upon clinical experience. The antimicrobials used to treat a specific pathogen causing PVE are generally the treatment used for that organism when it causes native valve endocarditis (NVE). Staphylococci, which commonly cause PVE, are an exception to this dictum. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/37/20058?source=see_link\">",
"     \"Antimicrobial therapy of native valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    No randomized controlled studies have evaluated the optimal duration of therapy for PVE. Treatment guidelines from the American Heart Association (AHA) and the European Society for Cardiology (ESC) recommend that PVE should be treated with an agent(s) that is bactericidal for the isolated microorganism for at least six weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. We generally agree with these guidelines and recommend a minimum of six weeks of treatment.",
"   </p>",
"   <p>",
"    There are small differences, described under each specific microorganism below, in recommended guidelines between the AHA and the ESC [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. We are in general agreement with these guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     STAPHYLOCOCCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment choices for staphylococcal prosthetic valve endocarditis (PVE) are not contingent on whether the pathogen is coagulase-negative or S. aureus, unlike most other types of staphylococcal infections (",
"    <a class=\"graphic graphic_table graphicRef61202 \" href=\"mobipreview.htm?8/61/9182\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The primary consideration in choosing therapy hinges upon whether or not the organism is sensitive to methicillin and other beta-lactam antibiotics. In addition, PVE caused by S. aureus frequently requires prompt surgical intervention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/32/3591?source=see_link&amp;anchor=H6#H6\">",
"     \"Surgery for prosthetic valve endocarditis\", section on 'Microorganisms usually requiring surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Antimicrobial treatment of staphylococcal PVE requires combination therapy. We agree with the AHA and ESC who recommend a triple drug regimen, as described below.",
"   </p>",
"   <p>",
"    Evidence to support a triple-drug regimen (with one drug being",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ) comes from animal models of prosthetic device infection and retrospective clinical series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/4,6-9\">",
"     4,6-9",
"    </a>",
"    ]. A retrospective study of valve cultures from 61 patients with staphylococcal PVE treated surgically found that valves from patients receiving combination therapy were 5.9 times more likely to be culture-negative than those receiving monotherapy when results were adjusted for duration of therapy before surgery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/6\">",
"     6",
"    </a>",
"    ]. Although the numbers are too small to analyze, all six patients who received a triple-drug regimen that included rifampin, had negative valve cultures at surgery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Methicillin susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    is the primary drug for isolates resistant to methicillin, while a semisynthetic penicillinase-resistant penicillin (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/36/1608?source=see_link\">",
"     nafcillin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    ) is the mainstay of therapy for isolates susceptible to methicillin. In patients with penicillin allergy that does not involve anaphylaxis, swelling, or hives, the AHA recommends that a first generation cephalosporin can substitute for nafcillin or oxacillin. We agree with this recommendation.",
"   </p>",
"   <p>",
"    If the organism is susceptible to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    by routine testing, this should be the second agent, with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    as the third agent (see",
"    <a class=\"local\" href=\"#H5\">",
"     'Rifampin'",
"    </a>",
"    below). The aminoglycoside should be administered for the initial two weeks of treatment, after which it can be discontinued and the other two agents continued for at least four additional weeks. If the organism is resistant to gentamicin, an alternative aminoglycoside should be sought based upon antibiotic susceptibilities.",
"   </p>",
"   <p>",
"    If the isolate is resistant to all available aminoglycosides, a fluoroquinolone to which the strain is highly susceptible should be used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. If a fluoroquinolone is used in lieu of an aminoglycoside, we prefer to continue the three-drug regimen for the entire course of treatment. When the isolate is resistant to all aminoglycosides and fluoroquinolones,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/13\">",
"     13",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/33/4628?source=see_link\">",
"     ceftaroline",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    could be considered as a third drug for the initial two weeks of therapy.",
"   </p>",
"   <p>",
"    If breakthrough bacteremia or microbiologic failure occurs in patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , the isolate recovered from the breakthrough bacteremia should be tested for the development of both vancomycin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    resistance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Optimal therapy of PVE caused by methicillin-resistant S. aureus with reduced",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    susceptibility or when failing vancomycin therapy has not been established. High-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    (if the isolate remains daptomycin susceptible),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?26/42/27301?source=see_link\">",
"     telavancin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/33/4628?source=see_link\">",
"     ceftaroline",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    are often active against these organisms, although clinical experience in the treatment of PVE is limited [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Rifampin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     Rifampin",
"    </a>",
"    appears to have the unique ability to kill staphylococci that are adherent to foreign material, based upon in vitro data, evidence from animal model experiments, and clinical observations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/4,8-12,18\">",
"     4,8-12,18",
"    </a>",
"    ]. This drug is an essential component of regimens used to treat staphylococcal PVE. However, bacterial cells have a relatively high intrinsic mutation rate for the gene controlling the rifampin site of action. These mutations allow the selection of a rifampin-resistant subpopulation when large numbers of staphylococci are exposed to ineffective rifampin-containing regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/4,10\">",
"     4,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To protect against the emergence of resistance, the recommended regimens for staphylococcal PVE (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Staphylococci'",
"    </a>",
"    above) ideally contain two additional antimicrobials, which should be identified prior to the initiation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , if at all possible. Thus, a regimen with two other drugs to which the staphylococci are susceptible should be in place at the time rifampin is begun. If the isolate is not sensitive to two additional antimicrobials, therapy with a single antistaphylococcal agent should be administered for three to five days before beginning rifampin. This strategy may reduce the total number of staphylococci at the site of infection and thus diminish the probability that a rifampin-resistant subpopulation will emerge. Nevertheless, susceptibility to rifampin should be reassessed when regimens containing rifampin fail [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     STREPTOCOCCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with a beta-lactam antibiotic and an aminoglycoside (if the isolate does not exhibit high level resistance to the aminoglycoside) is the preferred regimen for streptococcal prosthetic valve endocarditis (PVE). In an effort to provide maximal therapy, combination beta-lactam-aminoglycoside therapy is used to achieve synergistic killing of the organism. This synergistic interaction is similar to that seen with combination therapy for enterococcal endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on in vitro studies, clinical series, and experience of experts, penicillin plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    is recommended for the therapy of PVE caused by penicillin-susceptible streptococci (minimum inhibitory concentration [MIC] &le;0.12",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_table graphicRef61640 \" href=\"mobipreview.htm?21/24/21901\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/5,20\">",
"     5,20",
"    </a>",
"    ]. In the absence of high-level gentamicin resistance, gentamicin should be given during the initial two weeks of treatment. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Enterococci'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In the absence of high-level",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    resistance, streptomycin may be given in lieu of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    to achieve the same effect, but gentamicin is more commonly used in clinical practice due to the wider availability of gentamicin serum levels, and because dosing regimens for gentamicin are more familiar to most clinicians than dosing regimens for streptomycin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/21,22\">",
"     21,22",
"    </a>",
"    ]. For these reasons, we recommend gentamicin if the isolate is susceptible. Penicillin, a cephalosporin, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    can be used alone if aminoglycoside therapy is relatively contraindicated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the streptococcus is relatively resistant to penicillin (MIC &gt;0.12",
"    <span class=\"nowrap\">",
"     mcg/mL),",
"    </span>",
"    the AHA recommends that the aminoglycoside should be continued for the entire four to six weeks of therapy, if not precluded by nephrotoxicity (",
"    <a class=\"graphic graphic_table graphicRef71412 \" href=\"mobipreview.htm?19/54/20333\">",
"     table 3",
"    </a>",
"    ). Although there is a theoretical benefit to a longer course of aminoglycoside therapy when treating PVE caused by these less penicillin-susceptible strains, there are not sufficient data upon which to base recommendations on duration of therapy or dosing frequency. We would recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    be administered in three divided doses for two weeks when the isolate has penicillin MIC &gt;0.12",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    and for four to six weeks if the MIC &gt;0.5",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    or if PVE is caused by Abiotrophia defectiva, Granulicatella spp, or Gemella spp. We base these recommendations on limited data generated from native valve endocarditis treatment and the risk of enhanced aminoglycoside nephrotoxicity with longer courses of therapy. The ESC recommends that the aminoglycoside be given during the initial two weeks of treatment even when the isolate is relatively resistant to penicillin (MIC 0.125 to 2.0",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    and for three to four weeks if the MIC is &gt;2.0",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"   </p>",
"   <p>",
"    Among patients who are allergic to penicillin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    is advised for those with immediate type reactions (urticaria or anaphylaxis).",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"     Cefotaxime",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    may be used in non-immediate allergies. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15672?source=see_link\">",
"     \"Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ENTEROCOCCI",
"    </span>",
"    &nbsp;&mdash;&nbsp;To achieve bactericidal activity against enterococci requires the synergistic interaction of a cell wall active agent (penicillin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ) and an aminoglycoside (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    ) (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/37/20058?source=see_link\">",
"     \"Antimicrobial therapy of native valve endocarditis\"",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/19\">",
"     19",
"    </a>",
"    ]. To achieve this interaction the organism must not be resistant to the cell wall active agent at achievable serum concentrations and must not be resistant to gentamicin at 500",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    or streptomycin at 1000",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    in broth or at 2000",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    when using cultures on agar. Growth in the presence of the aminoglycoside at these concentrations indicates high-level resistance and precludes synergy when the aminoglycoside is used. Resistance to gentamicin at this concentration also indicates that synergy cannot be achieved with netilmicin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/35/34352?source=see_link\">",
"     tobramycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/10/40102?source=see_link\">",
"     kanamycin",
"    </a>",
"    . High-level resistance to gentamicin and streptomycin are mediated by two independently acquired genes; hence, organisms should be tested for high-level resistance to each of these drugs.",
"   </p>",
"   <p>",
"    Based on in vitro studies, animal models, and clinical series [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/23\">",
"     23",
"    </a>",
"    ], we, along with the AHA and ESC recommend combination therapy with a cell wall active agent (penicillin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ) plus an aminoglycoside (usually",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    ) for treatment of PVE caused by enterococci (as long as the strain is confirmed to be susceptible).",
"   </p>",
"   <p>",
"    Cephalosporins are not usually active against enterococci and also do not interact with aminoglycosides to result in bactericidal synergy. The cephalosporins should not be used alone as the cell wall active agent in the treatment of enterococcal PVE in patients allergic to penicillin. Rather, such patients should be treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    plus an aminoglycoside. When the risk of nephrotoxicity with this regimen is unacceptable, patients should be desensitized to penicillin to allow treatment with penicillin or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    plus an aminoglycoside. In past years, the regimens outlined for treatment of enterococcal PVE in the following tables had been predictably bactericidal (",
"    <a class=\"graphic graphic_table graphicRef71888 \" href=\"mobipreview.htm?30/47/31485\">",
"     table 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef52963 \" href=\"mobipreview.htm?21/45/22237\">",
"     table 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/23\">",
"     23",
"    </a>",
"    ]. However, antibiotic resistance among enterococci has become significantly more common, necessitating that each strain causing endocarditis be carefully tested in order to select a synergistic regimen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     Penicillin/",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"      ampicillin",
"     </a>",
"    </span>",
"    resistance will most commonly be due to alterations in penicillin-binding proteins. In that situation,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    is the cell-active agent of choice. Occasionally, E. faecalis may be resistant to penicillin and ampicillin by virtue of beta-lactamase production. In this instance vancomycin or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    could be used. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/56/26506?source=see_link\">",
"     \"Mechanisms of antibiotic resistance in enterococci\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If the enterococcus has high-level resistance to both",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    , synergy is not feasible and an aminoglycoside should",
"    <strong>",
"     not",
"    </strong>",
"    be administered. When resistance precludes bactericidal therapy, a prolonged course of 8 to 12 weeks of one of the cell wall active agents should be administered instead, but therapy in patients with native valve endocarditis has only a 40 percent chance of being successful [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/26\">",
"     26",
"    </a>",
"    ]. Data in native valve E. faecalis endocarditis suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    (2 g every 4 hours) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 g every 12 hours) for six weeks may yield superior cure rates than single drug therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/27\">",
"     27",
"    </a>",
"    ]. Surgery may be indicated for patients not sufficiently responsive to therapy.",
"   </p>",
"   <p>",
"    Although the data are limited, in the setting of progressive nephrotoxicity, the duration of aminoglycoside administration may be reduced to less than six weeks with no decrease in cure rates. This was illustrated in a prospective study from Sweden of 93 episodes of enterococcal endocarditis that included 27 cases of prosthetic valve endocarditis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/28\">",
"     28",
"    </a>",
"    ]. Clinical cure was achieved in 75 of 93 episodes (81 percent) overall, and in 21 of 27 (78 percent) with PVE. In patients who achieved clinical cure, a cell wall-active antimicrobial therapy was given for a median of 42 days, and a synergistic aminoglycoside was added for a median of 15 days.",
"   </p>",
"   <p>",
"    Optimal therapy of PVE caused by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    -resistant E. faecium (VRE) organisms, which often are also resistant to penicillin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    , and highly resistant to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"     streptomycin",
"    </a>",
"    , has not been established. VRE are occasionally susceptible to penicillin and ampicillin and may not have high-level resistance to streptomycin and gentamicin. A full evaluation of the isolates resistance profile is required to select optimal therapy. Although",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/17/34068?source=see_link\">",
"     quinupristin-dalfopristin",
"    </a>",
"    (E. faecium only) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/3/14393?source=see_link\">",
"     linezolid",
"    </a>",
"    (E. faecium and E. faecalis) are often active against these organisms, their effectiveness in the treatment of PVE caused by VRE is not known [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/29\">",
"     29",
"    </a>",
"    ]. In general,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?20/10/20646?source=see_link\">",
"     daptomycin",
"    </a>",
"    is active against enterococci, including VRE, although there are no approved susceptibility breakpoints for daptomycin (enterococci with MIC &gt;4.0",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    are likely resistant). Clinical experience with daptomycin is limited to case reports, raising important concerns regarding reporting bias [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/30\">",
"     30",
"    </a>",
"    ]. Management of enterococcal endocarditis in circumstances where resistance precludes use of standard regimens should prompt infectious disease consultation.",
"   </p>",
"   <p>",
"    Surgical intervention during suppressive bacteriostatic therapy should be strongly considered when PVE is caused by highly resistant enterococci. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/62/14314?source=see_link\">",
"     \"Treatment of enterococcal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     HACEK",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because some of these organisms are",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"     ampicillin",
"    </a>",
"    -resistant due to the production of beta-lactamase, and all are highly susceptible to third generation cephalosporins, we, along with the AHA recommend therapy for HACEK PVE with one of the following antibiotics:",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/57/35735?source=see_link\">",
"     cefotaxime",
"    </a>",
"    , or a comparable third generation cephalosporin;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    ; or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    (recommended only for patients unable to tolerate cephalosporin or ampicillin therapy), administered for six weeks (",
"    <a class=\"graphic graphic_table graphicRef81524 \" href=\"mobipreview.htm?29/45/30428\">",
"     table 6",
"    </a>",
"    ). The ESC recommends ampicillin (if the organism is susceptible) or a third generation cephalosporin. Patients with HACEK PVE, who do not have valvular dysfunction, generally can be cured with antibiotics alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CORYNEBACTERIA (DIPHTHEROIDS)",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the strain is susceptible to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    (MIC &lt;4.0",
"    <span class=\"nowrap\">",
"     mcg/mL),",
"    </span>",
"    penicillin plus gentamicin will result in synergistic bactericidal activity and is recommended as therapy. Gentamicin resistance precludes bactericidal synergy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/32\">",
"     32",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     Vancomycin",
"    </a>",
"    is bactericidal against diphtheroids and is recommended for therapy when strains are resistant to gentamicin or when patients are allergic to penicillin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GRAM-NEGATIVE BACILLI",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend treatment of PVE caused by gram-negative bacilli be based upon the susceptibility of the causative organism. Where possible, a synergistic bactericidal regimen should be used. Treatment for Pseudomonas aeruginosa is based upon experience in patients with NVE. If the organism is susceptible, high dose",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/tobramycin-drug-information?source=see_link\">",
"     tobramycin",
"    </a>",
"    (8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day IV or intramuscularly in once-daily doses with maintenance of peak and trough concentrations of 15 to 20",
"    <span class=\"nowrap\">",
"     mcg/mL",
"    </span>",
"    and less than or equal to 2",
"    <span class=\"nowrap\">",
"     mcg/mL,",
"    </span>",
"    respectively) plus ticarcillin,",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/piperacillin-drug-information?source=see_link\">",
"     piperacillin",
"    </a>",
"    ,",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/cefepime-drug-information?source=see_link\">",
"     cefepime",
"    </a>",
"    , or",
"    <a class=\"external\" href=\"file://www.uptodate.com/contents/ceftazidime-drug-information?source=see_link\">",
"     ceftazidime",
"    </a>",
"    is recommended [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/37/20058?source=see_link\">",
"     \"Antimicrobial therapy of native valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Surgery to excise the infected valve is often required in gram-negative bacillus endocarditis, especially that caused by P. aeruginosa or when infection involves the left-sided heart valves. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/32/3591?source=see_link\">",
"     \"Surgery for prosthetic valve endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     FUNGI",
"    </span>",
"    &nbsp;&mdash;&nbsp;No randomized, controlled studies have evaluated the optimal therapy for fungal PVE. We, along with most infectious disease specialists, recommend a combined approach that utilizes both antifungal agents and valve replacement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/33\">",
"     33",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     Amphotericin B",
"    </a>",
"    (daily doses ranging from 0.7 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) is the antimicrobial of choice for treatment of fungal PVE as the greatest clinical experience in treating fungal PVE is with this agent.",
"   </p>",
"   <p>",
"    For the treatment of endocarditis caused by mycelial fungi, such as Aspergillus or Mucor species, somewhat larger doses are used (1.0 to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day). We recommend for the treatment of fungal endocarditis,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    be combined with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32773?source=see_link\">",
"     flucytosine",
"    </a>",
"    (150",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided into four doses with adjustments for renal dysfunction) in an attempt to achieve a synergistic effect. This initial phase of treatment is usually given for at least six weeks. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43190?source=see_link\">",
"     \"Pharmacology of flucytosine (5-FC)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The use of a lipid formulation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    in lieu of amphotericin B deoxycholate for the treatment of fungal endocarditis has not been evaluated. Nevertheless, if renal dysfunction complicates amphotericin B treatment, substitution of a lipid formulation is justified.",
"   </p>",
"   <p>",
"    Early surgical intervention is considered by most experts to be a standard element of treatment for fungal PVE. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/32/3591?source=see_link&amp;anchor=H6#H6\">",
"     \"Surgery for prosthetic valve endocarditis\", section on 'Microorganisms usually requiring surgery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the potential for relapse is high in Candida PVE, even with surgical intervention, we along with most infectious disease specialists recommend a suppressive second phase of oral therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    (200 to 400 mg daily or another triazole) for prolonged periods, if not indefinitely [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/34-36\">",
"     34-36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40566?source=see_link\">",
"     \"Candida endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Successful treatment of Candida PVE without surgery has been reported in a few case reports using a combination regimen of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/12/16586?source=see_link\">",
"     fluconazole",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/15/10486?source=see_link\">",
"     caspofungin",
"    </a>",
"    or fluconazole and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/53/43863?source=see_link\">",
"     amphotericin B",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     CULTURE-NEGATIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many native and prosthetic valve endocarditis patients with negative blood cultures have been rendered culture-negative by virtue of prior antibiotic therapy. The therapy to which they have been exposed is a clue and consideration in selecting empiric treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34646?source=see_link\">",
"     \"Culture-negative endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of clinical clues to a specific etiology, we along with the AHA recommend that treatment for culture-negative PVE, with onset within the first year following valve surgery, should include",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/33/16919?source=see_link\">",
"     cefepime",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/1\">",
"     1",
"    </a>",
"    ]. The ESC recommendations for this group omit cefepime [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/2\">",
"     2",
"    </a>",
"    ]. For initial therapy of PVE with onset greater than one year after surgery, the AHA and the ESC recommend treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/8/1160?source=see_link\">",
"     ampicillin-sulbactam",
"    </a>",
"    plus gentamicin or vancomycin, gentamicin and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The AHA recommends the addition of rifampin to these regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/1\">",
"     1",
"    </a>",
"    ]. For patients with the onset of disease 12 months or more after valve implantation where Bartonella is suspected, the AHA and we recommend treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    , gentamicin, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/1\">",
"     1",
"    </a>",
"    ]. Aggressive efforts must be made to identify a causative agent and specific therapy defined, since treatment regimens for the causes of true blood culture-negative endocarditis vary widely (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=see_link&amp;anchor=H23#H23\">",
"     \"Diagnostic approach to infective endocarditis\", section on 'Culture-negative endocarditis'",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Epidemiologic considerations should be weighed carefully. As an example, in some regions of the world Coxiella burnetii is a common cause of culture-negative PVE. The possibility of fungal endocarditis should be considered, especially in patients with a complex perioperative course. If unexplained fever persists in the face of empiric therapy, surgery to obtain a vegetation for microbiologic evaluation should be considered [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34712/abstract/4,20\">",
"     4,20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15255?source=see_link\">",
"     \"Q fever endocarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of prosthetic valve endocarditis is more difficult than treatment of native valve endocarditis and may require surgical replacement of the prostheses in addition to antibiotic therapy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The antimicrobial regimens used are targeted to a specific pathogen, thus identification of the causative organism is critical. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=see_link\">",
"       \"Diagnostic approach to infective endocarditis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We recommend the same treatment regimens for a specific pathogen causing PVE as is used for that organism when it causes native valve endocarditis (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). An exception is staphylococcal endocarditis; for this microorganism we recommend treatment with three agents in combination, with one of these being",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H3\">",
"       'Staphylococci'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend treatment of PVE with an agent(s) that is bactericidal for the isolated microorganism for at least six weeks (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment choices for staphylococcal PVE are the same regardless of whether the pathogen is coagulase-negative staphylococcus or S. aureus. The primary consideration in choosing therapy hinges upon whether or not the organism is sensitive to methicillin. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Staphylococci'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend a treatment regimen for enterococcal PVE that includes the synergistic interaction of a cell wall active agent (penicillin,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/51/13112?source=see_link\">",
"       ampicillin",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"       vancomycin",
"      </a>",
"      ) and an aminoglycoside (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/10/36000?source=see_link\">",
"       gentamicin",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?18/9/18583?source=see_link\">",
"       streptomycin",
"      </a>",
"      ). (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Enterococci'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/1\">",
"      Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation 2005; 111:e394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/2\">",
"      Habib G, Hoen B, Tornos P, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. Eur Heart J 2009; 30:2369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/3\">",
"      American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 guidelines for the management of patients with valvular heart disease), Society of Cardiovascular Anesthesiologists, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (writing Committee to Revise the 1998 guidelines for the management of patients with valvular heart disease) developed in collaboration with the Society of Cardiovascular Anesthesiologists endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2006; 48:e1.",
"     </a>",
"    </li>",
"    <li>",
"     Karchmer AW. Infections of Prosthetic Heart Valves. In: Infections Associated with Indwelling Medical Devices, 3rd ed, Waldvogel FA, Bisno AL (Eds), American Society for Microbiology, Washington, DC 2000. p.145.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/5\">",
"      Wilson WR, Karchmer AW, Dajani AS, et al. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. JAMA 1995; 274:1706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/6\">",
"      Drinkovi D, Morris AJ, Pottumarthy S, et al. Bacteriological outcome of combination versus single-agent treatment for staphylococcal endocarditis. J Antimicrob Chemother 2003; 52:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/7\">",
"      Karchmer AW, Archer GL, Dismukes WE. Rifampin treatment of prosthetic valve endocarditis due to Staphylococcus epidermidis. Rev Infect Dis 1983; 5 Suppl 3:S543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/8\">",
"      Archer GL, Johnston JL, Vazquez GJ, Haywood HB 3rd. Efficacy of antibiotic combinations including rifampin against methicillin-resistant Staphylococcus epidermidis: in vitro and in vivo studies. Rev Infect Dis 1983; 5 Suppl 3:S538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/9\">",
"      Kobasa WD, Kaye KL, Shapiro T, Kaye D. Therapy for experimental endocarditis due to Staphylococcus epidermidis. Rev Infect Dis 1983; 5 Suppl 3:S533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/10\">",
"      Chuard C, Herrmann M, Vaudaux P, et al. Successful therapy of experimental chronic foreign-body infection due to methicillin-resistant Staphylococcus aureus by antimicrobial combinations. Antimicrob Agents Chemother 1991; 35:2611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/11\">",
"      Lucet JC, Herrmann M, Rohner P, et al. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1990; 34:2312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/12\">",
"      Rouse MS, Wilcox RM, Henry NK, et al. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus epidermidis. Antimicrob Agents Chemother 1990; 34:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/13\">",
"      Souli M, Pontikis K, Chryssouli Z, et al. Successful treatment of right-sided prosthetic valve endocarditis due to methicillin-resistant teicoplanin-heteroresistant Staphylococcus aureus with linezolid. Eur J Clin Microbiol Infect Dis 2005; 24:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/14\">",
"      Cubicin resistance should be closely monitored in bacteremia patients. The Pink Sheet 2006; 68:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/15\">",
"      Mohan SS, McDermott BP, Cunha BA. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin. Heart Lung 2005; 34:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/16\">",
"      Howden BP, Ward PB, Charles PG, et al. Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility. Clin Infect Dis 2004; 38:521.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/17\">",
"      Moore CL, Osaki-Kiyan P, Haque NZ, et al. Daptomycin versus vancomycin for bloodstream infections due to methicillin-resistant Staphylococcus aureus with a high vancomycin minimum inhibitory concentration: a case-control study. Clin Infect Dis 2012; 54:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/18\">",
"      Karchmer AW, Archer GL, Dismukes WE. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiologic and clinical observations as guides to therapy. Ann Intern Med 1983; 98:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/19\">",
"      Matsumoto JY, Wilson WR, Wright AJ, et al. Synergy of penicillin and decreasing concentration of aminoglycosides against enterococci from patients with infective endocarditis. Antimicrob Agents Chemother 1980; 18:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/20\">",
"      Bayer AS, Bolger AF, Taubert KA, et al. Diagnosis and management of infective endocarditis and its complications. Circulation 1998; 98:2936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/21\">",
"      Farber BF, Eliopoulos GM, Ward JI, et al. Resistance to penicillin-streptomycin synergy among clinical isolates of viridans streptococci. Antimicrob Agents Chemother 1983; 24:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/22\">",
"      Enzler MJ, Rouse MS, Henry NK, et al. In vitro and in vivo studies of streptomycin-resistant, penicillin-susceptible streptococci from patients with infective endocarditis. J Infect Dis 1987; 155:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/23\">",
"      Rice LB, Calderwood SB, Eliopoulos GM, et al. Enterococcal endocarditis: a comparison of prosthetic and native valve disease. Rev Infect Dis 1991; 13:1.",
"     </a>",
"    </li>",
"    <li>",
"     Eliopoulos GM. Enterococcal endocarditis. In: Infective Endocarditis, Kaye D (Ed), Raven Press, New York 1992. p.209.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/25\">",
"      Eliopoulos GM. Aminoglycoside resistant enterococcal endocarditis. Infect Dis Clin North Am 1993; 7:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/26\">",
"      GERACI JE, MARTIN WJ. Antibiotic therapy of bacterial endocarditis. VI. Subacute enterococcal endocarditis; clinical, pathologic and therapeutic consideration of 33 cases. Circulation 1954; 10:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/27\">",
"      Gavald&agrave; J, Len O, Mir&oacute; JM, et al. Brief communication: treatment of Enterococcus faecalis endocarditis with ampicillin plus ceftriaxone. Ann Intern Med 2007; 146:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/28\">",
"      Olaison L, Schadewitz K, Swedish Society of Infectious Diseases Quality Assurance Study Group for Endocarditis. Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides be used? Clin Infect Dis 2002; 34:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/29\">",
"      Rao N, White GJ. Successful treatment of Enterococcus faecalis prosthetic valve endocarditis with linezolid. Clin Infect Dis 2002; 35:902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/30\">",
"      Levine DP, Lamp KC. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. Am J Med 2007; 120:S28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/31\">",
"      Meyer DJ, Gerding DN. Favorable prognosis of patients with prosthetic valve endocarditis caused by gram-negative bacilli of the HACEK group. Am J Med 1988; 85:104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/32\">",
"      Murray BE, Karchmer AW, Moellering RC Jr. Diphtheroid prosthetic valve endocarditis. A study of clinical features and infecting organisms. Am J Med 1980; 69:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/33\">",
"      Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/34\">",
"      Gilbert HM, Peters ED, Lang SJ, Hartman BJ. Successful treatment of fungal prosthetic valve endocarditis: case report and review. Clin Infect Dis 1996; 22:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/35\">",
"      Melgar GR, Nasser RM, Gordon SM, et al. Fungal prosthetic valve endocarditis in 16 patients. An 11-year experience in a tertiary care hospital. Medicine (Baltimore) 1997; 76:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/36\">",
"      Nguyen MH, Nguyen ML, Yu VL, et al. Candida prosthetic valve endocarditis: prospective study of six cases and review of the literature. Clin Infect Dis 1996; 22:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/37\">",
"      Lye DC, Hughes A, O'Brien D, Athan E. Candida glabrata prosthetic valve endocarditis treated successfully with fluconazole plus caspofungin without surgery: a case report and literature review. Eur J Clin Microbiol Infect Dis 2005; 24:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34712/abstract/38\">",
"      Aaron L, Therby A, Viard JP, et al. Successful medical treatment of Candida albicans in mechanical prosthetic valve endocarditis. Scand J Infect Dis 2003; 35:351.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2141 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-D4C8FA2A70-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_57_34712=[""].join("\n");
var outline_f33_57_34712=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      STAPHYLOCOCCI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Methicillin susceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Rifampin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      STREPTOCOCCI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ENTEROCOCCI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      HACEK",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CORYNEBACTERIA (DIPHTHEROIDS)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GRAM-NEGATIVE BACILLI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      FUNGI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      CULTURE-NEGATIVE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/2141\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/2141|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/61/9182\" title=\"table 1\">",
"      Rx staph PVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/24/21901\" title=\"table 2\">",
"      Rx strep PVE I",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/54/20333\" title=\"table 3\">",
"      Rx strep PVE II",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/47/31485\" title=\"table 4\">",
"      Rx entero PVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/45/22237\" title=\"table 5\">",
"      Rx entero PVEII",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?29/45/30428\" title=\"table 6\">",
"      Rx HACEK PVE",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/37/20058?source=related_link\">",
"      Antimicrobial therapy of native valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/39/40566?source=related_link\">",
"      Candida endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/53/34646?source=related_link\">",
"      Culture-negative endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/24/41352?source=related_link\">",
"      Diagnostic approach to infective endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/40/2697?source=related_link\">",
"      Epidemiology, clinical manifestations, and diagnosis of prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/56/26506?source=related_link\">",
"      Mechanisms of antibiotic resistance in enterococci",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/19/15672?source=related_link\">",
"      Penicillin-allergic patients: Use of cephalosporins, carbapenems, and monobactams",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/11/43190?source=related_link\">",
"      Pharmacology of flucytosine (5-FC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/57/15255?source=related_link\">",
"      Q fever endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/32/3591?source=related_link\">",
"      Surgery for prosthetic valve endocarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/62/14314?source=related_link\">",
"      Treatment of enterococcal infections",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_57_34713="Med bronchogen cyst CXR II";
var content_f33_57_34713=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55788%7EPULM%2F63545%7EPULM%2F65152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55788%7EPULM%2F63545%7EPULM%2F65152&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infected subcarinal bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows a bronchogenic cyst prior to infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infected subcarinal bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows a bronchogenic cyst after infection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Infected subcarinal bronchogenic cyst",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 281px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A CT scan with soft tissue and lung window settings shows a gas containing cyst, surrounded by ground-glass opacity and consolidation in the right lower lobe, which represents a pneumonia that caused infection of the adjacent bronchogenic cyst.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_57_34713=[""].join("\n");
var outline_f33_57_34713=null;
var title_f33_57_34714="Treatment of primary focal segmental glomerulosclerosis";
var content_f33_57_34714=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of primary focal segmental glomerulosclerosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/57/34714/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/57/34714/contributors\">",
"     Gerald B Appel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/57/34714/contributors\">",
"     Daniel C Cattran, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/57/34714/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/57/34714/contributors\">",
"     Richard J Glassock, MD, MACP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?33/57/34714/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?33/57/34714/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?33/57/34714/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal segmental glomerulosclerosis (FSGS) is a histologic diagnosis that may be found either without an identifiable cause (in which case it is called \"idiopathic\" or \"primary\") or in response to previous glomerular injury, glomerular hypertension, or hypertrophy (\"secondary\") [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/1\">",
"     1",
"    </a>",
"    ]. Primary FSGS may present acutely with overt nephrotic syndrome with hypoalbuminemia and edema or, less often, insidiously with less dramatic manifestations, possibly related to the underlying histologic variant. In contrast, secondary FSGS most often presents as asymptomatic proteinuria without hypoalbuminemia or edema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/2\">",
"     2",
"    </a>",
"    ]. Distinguishing between",
"    <strong>",
"     primary and secondary disease",
"    </strong>",
"    is particularly important because of the markedly different approach to therapy in the two disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H13#H13\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Secondary FSGS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary FSGS was previously considered to be largely unresponsive to immunosuppressive therapy; however, glucocorticoids,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , and other immunosuppressive agents have been used with considerable therapeutic success. In contrast, immunosuppression is not indicated in secondary FSGS.",
"   </p>",
"   <p>",
"    Renin-angiotensin-aldosterone system blockade (with angiotensin converting enzyme [ACE] inhibitors or angiotensin receptor blockers [ARBs]) reduce proteinuria and slow progression in proteinuric kidney diseases, and are therefore likely to be beneficial in primary and secondary FSGS. Among the rare patients with FSGS related to malignancy, effective therapy of the malignancy may lead to remission of the proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the prognosis and treatment of primary FSGS in adults, focusing on patients with nephrotic range proteinuria. The causes of FSGS and the treatment of children with FSGS are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=see_link\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following discussion does not apply to collapsing FSGS, which may be associated with HIV and a variety of other conditions. This variant is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/3/2104?source=see_link\">",
"     \"HIV-associated nephropathy (HIVAN)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/31/43512?source=see_link\">",
"     \"Collapsing focal segmental glomerulosclerosis not associated with HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential efficacy of therapy must be considered in relation to the natural history of the disease. Untreated primary FSGS often follows a progressive course to end-stage renal disease (ESRD). The rate of spontaneous complete remission among patients with nephrotic syndrome is unknown, but is probably less than 10 percent. Spontaneous remission is more likely to occur among patients with normal kidney function and non-nephrotic proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Previously, treatment was not considered to substantially improve the prognosis of FSGS. However, longer courses of treatment have resulted in response rates of up to 70 percent and improved overall prognosis. Whether the outcome of patients who present with a substantial reduction in kidney function can be altered is less clear. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Prognostic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Factors that appear to influence response to treatment",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    prognosis principally include degree of proteinuria and renal dysfunction, histologic findings, and the response to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Degree of proteinuria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with the nephrotic syndrome (proteinuria &ge;3.0 or 3.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and low plasma albumin concentration) have five-year renal survival rates of 60 to 90 percent, and 10-year renal survival rates of 30 to 55 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Massive proteinuria (&gt;10",
"    <span class=\"nowrap\">",
"     g/day),",
"    </span>",
"    when unresponsive to treatment, is associated with an even worse prognosis, with most patients progressing to ESRD within five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/5\">",
"     5",
"    </a>",
"    ]. In contrast, renal survival is much better in patients without nephrotic syndrome, especially when this is associated with normal renal function (over 85 percent renal survival at 10 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of spontaneous complete remission among patients with nephrotic range proteinuria is unknown, since most patients are treated. It is probably less than 10 percent; slightly higher spontaneous remission rates in some reports may reflect more widespread use of ACE inhibitors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/5,10-12\">",
"     5,10-12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Severity of renal dysfunction",
"    </span>",
"    &nbsp;&mdash;&nbsp;More severe renal dysfunction at presentation is generally associated with worse renal survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. In one series, for example, patients with a plasma creatinine concentration of greater than 1.3",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (115",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    had a significantly decreased 10-year renal survival (27 versus 100 percent for those with a lower plasma creatinine) that was independent of the degree of proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/14\">",
"     14",
"    </a>",
"    ]. Worse renal function at presentation (unless it is acute) is generally associated with a greater extent of fibrosis on biopsy (reflecting more severe disease, disease of longer duration, or other factors such as hypertension or aging); therefore, it is less likely to respond to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Histologic findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of interstitial fibrosis at the time of presentation uniformly predicts poor renal survival, although this may reflect secondary FSGS in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/7,15-17\">",
"     7,15-17",
"    </a>",
"    ]. The collapsing variant is particularly associated with a worse prognosis and is often considered a different disorder. Although the association of other histologic findings with prognosis is less clear, patients with segmental scarring at the tubular pole of the glomeruli, the so-called \"glomerular tip lesion\" (",
"    <a class=\"graphic graphic_picture graphicRef66716 \" href=\"mobipreview.htm?8/53/9050\">",
"     picture 1",
"    </a>",
"    ), have been considered more likely to respond to steroid therapy or to spontaneously remit (if renal function is normal), although this remains under considerable debate, and the presence of this lesion does not guarantee responsiveness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/4,17-20\">",
"     4,17-20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Interestingly, focal \"global\" sclerosis (eg, lesions that involve most or all of the glomerular tuft, not just segments) was associated with steroid responsiveness in a small study of children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/21\">",
"     21",
"    </a>",
"    ]. One possible explanation is that these patients actually had minimal change disease and the totally sclerotic glomeruli reflected prior damage. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Glucocorticoid resistance'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Response to therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The strongest prognostic indicator of outcome is the initial response to therapy regardless of the type of histology. Response is reported in terms of degree of reduction in proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/5,13,22,23\">",
"     5,13,22,23",
"    </a>",
"    ]. We propose the following definitions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A complete response is a reduction in proteinuria to &lt;200 to 300",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      A partial response in patients presenting with nephrotic range proteinuria is a reduction of &ge;50 percent, and to less than 3.5",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"     </li>",
"     <li>",
"      A relapse is return of proteinuria to &ge;3.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      in someone who had undergone a complete or partial remission.",
"     </li>",
"     <li>",
"      Steroid-dependence refers to relapse while on therapy or requirement for continuation of steroids to maintain remission.",
"     </li>",
"     <li>",
"      Steroid-resistance refers to little or no reduction in proteinuria after 12 to 16 weeks of adequate",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      therapy in an adult, or to patients who have some reduction in proteinuria with more prolonged therapy who do not meet the criteria for partial remission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some investigators also include normalization of the plasma albumin concentration in the definition of response. Patients who undergo partial or complete remission have a much better chance of renal survival (approximately 80 versus &lt;50 percent at 10 years in nonresponders and untreated patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/5,6,9,11,13,16,18,24\">",
"     5,6,9,11,13,16,18,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    General outcomes with respect to response to therapy, including the prognosis associated with partial remissions and relapses, were perhaps best shown in a retrospective study of 281 FSGS patients with the nephrotic syndrome who were followed for a minimum of one year in the Toronto Glomerulonephritis Registry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/13\">",
"     13",
"    </a>",
"    ]. Two-thirds of the patients received immunosuppressive therapy, including high-dose glucocorticoids (50 percent), cytotoxic agents (19 percent), or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    (12 percent). Over one-half of patients also received an ACE inhibitor or ARB.",
"   </p>",
"   <p>",
"    At a median follow-up of 64 months, a complete, partial, or no remission was observed in 20, 41, and 39 percent, respectively. The time to remission was 12 to 14 months. Relapses occurred less frequently in those who had a complete remission (36 versus 52 percent among partial responders). Renal failure occurred in 6, 18, and 45 percent of patients with a complete, partial, or no remission, respectively. Patients who remained in remission had a slower rate of decline in renal function and a lower risk of renal failure compared to those who experienced a later relapse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Disease progression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease progression, either by worsening renal function or, in some studies, histologic parameters, may occur despite partial remission of proteinuria. Some patients have a modest increase in the plasma creatinine concentration and, on repeat renal biopsy, an increased number of glomeruli with segmental or global sclerosis and more severe tubulointerstitial disease. This may be in part due to bias in the selection of patients for repeat biopsy and tissue sampling bias given the focal nature of the disease. However, it may also reflect a low level of continued disease activity, healing of previous injury, or secondary hemodynamic damage (which may be minimized by administration of an ACE inhibitor or ARB). (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Nonimmunosuppressive therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although less responsive than minimal change disease, primary FSGS appears to respond to glucocorticoids, as well as other agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/16\">",
"     16",
"    </a>",
"    ]; however, more prolonged glucocorticoid therapy than in minimal change disease is generally required to induce remission.",
"   </p>",
"   <p>",
"    For the treatment of steroid-resistant or relapsing disease,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is most commonly used, although other agents, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , have been tried with various degrees of response in a small number of cases.",
"   </p>",
"   <p>",
"    Although not specifically studied in primary or secondary FSGS, ACE inhibitors or ARBs reduce proteinuria and slow progression in proteinuric kidney diseases, and are therefore indicated in all patients with primary FSGS whether or not immunosuppressive therapy is provided. In addition, patients with nephrotic syndrome are often hypercholesterolemic and require appropriate statin therapy. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Nonimmunosuppressive therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    These recommendations do not apply to collapsing FSGS, the treatment of which is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/3/2104?source=see_link\">",
"     \"HIV-associated nephropathy (HIVAN)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/31/43512?source=see_link\">",
"     \"Collapsing focal segmental glomerulosclerosis not associated with HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Initial immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recommendations for initial therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    are solely based upon observational studies and the authors' clinical experience. There are no randomized trials comparing prednisone or other agents to placebo for initial therapy of primary FSGS. Prednisone induces complete or partial remission in 40 to 80 percent of patients with relatively preserved renal function and, as noted above, responders have better long-term outcomes. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Glucocorticoid studies'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    It is not possible to confidently predict at presentation which patients will respond to steroids. In addition, a small number of patients with primary FSGS will spontaneously remit and have a good prognosis and will not require immunosuppressive therapy. These patients, however, are also not predictable at presentation. Perhaps more important to weigh are the risks and benefits of steroid therapy in the elderly patients or those with co-morbid conditions.",
"   </p>",
"   <p>",
"    We generally provide immunosuppressive therapy to patients with primary FSGS who present with nephrotic range proteinuria.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    is usually administered for a minimum of 12 to 16 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. The efficacy of immunosuppression in patients with significantly decreased kidney function (eg, GFR &lt;25 to 35",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) is unclear. The decision should take into consideration the acuity of the renal failure (better response with acute disease), the findings on renal biopsy (eg, poor response with the presence of significant tubulointerstitial fibrosis and glomerulosclerosis), and the patient's risk for adverse consequences related to immunosuppression. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Monitoring response to and duration of therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    We generally do not initiate immunosuppressive therapy in patients with the following clinical features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Normal kidney function and less than nephrotic-range proteinuria. These individuals usually have a relatively indolent course and may have spontaneous remission or stabilization of proteinuria; progression is more likely with higher degrees of proteinuria within the sub nephrotic range.",
"     </li>",
"     <li>",
"      Decreased kidney function and less than nephrotic-range proteinuria. These patients may have had more severe proteinuria at an earlier stage of their disease that went undetected, or they may have secondary FSGS. Response to therapy in such individuals is poor. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These patients should receive nonimmunologic therapy with ACE inhibitors",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    ARBs to slow disease progression. (See",
"    <a class=\"local\" href=\"#H25\">",
"     'Nonimmunosuppressive therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although data are limited, we may use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    as initial therapy, in conjunction with low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , in patients at increased risk for glucocorticoid-associated toxicity. Potential candidates for this approach are the obese, patients with diabetes or at high risk for developing diabetes, patients with severe osteoporosis, and older patients. We avoid using calcineurin inhibitors in patients who have significant vascular or interstitial disease on renal biopsy, or an estimated GFR &lt;40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 because of the potential nephrotoxicity of these drugs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Glucocorticoid studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonrandomized retrospective studies utilizing a variety of glucocorticoid doses have reported 40 to 80 percent rates of complete (proteinuria &lt;200 or 300",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    or partial remission (variably defined as &lt;2 to 3.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    &ge;50 percent decrease in proteinuria) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/5,10,11,13,16,18,24,27\">",
"     5,10,11,13,16,18,24,27",
"    </a>",
"    ]. One report, for example, evaluated the course of 55 adults with a mean creatinine clearance of 90",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    at a mean follow-up of 11 years; 18 were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , seven also received",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and the remainder were not treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/10\">",
"     10",
"    </a>",
"    ]. Among the 18 treated patients, 8 (44 percent) achieved complete remission (one received cyclophosphamide in combination with glucocorticoids, another as secondary treatment after relapse), compared to 4 of 37 (11 percent) untreated patients (two of whom were never nephrotic). ESRD occurred significantly less often in treated nephrotic patients (29 versus 53 percent in untreated nephrotic patients).",
"   </p>",
"   <p>",
"    Another study described renal survival in 60 nephrotic and 21 non-nephrotic patients with FSGS; the serum creatinine at biopsy was 2.3 and 1.8",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (203 and 160",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    among nephrotic and non-nephrotic patients, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/5\">",
"     5",
"    </a>",
"    ]. Half of the nephrotic patients were treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . The 5- and 10-year renal survival in the non-nephrotic patients was 92 percent, compared with 76 and 57 percent among nephrotic patients. Among the treated nephrotic patients, half responded. The 5- and 10-year renal survival among responders was 100 percent, compared with 65 and 40 percent among nonresponders, respectively. Similar findings have been described by others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the presence of nephrotic syndrome, the level of kidney function was predictive of response to treatment in some [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/11,13,27\">",
"     11,13,27",
"    </a>",
"    ], but not all studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. In the one study providing a stratified analysis, remission was achieved in only 5 of 21 patients with a serum creatinine &gt;1.4",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (124",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    compared to 36 of 60 with lower serum creatinine concentrations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Race may also affect the response to steroid therapy. In a retrospective review of 72 individuals with primary FSGS, of whom 65 were African Americans, 60 percent received steroid therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/28\">",
"     28",
"    </a>",
"    ]. The mean maximum dose was 60",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    and duration including taper was almost one year. At a mean follow-up of approximately four years, 26 and 21 percent of the treated and untreated patients, respectively, reached ESRD, all of whom were African American. However, this retrospective study does not preclude the possibility that African Americans might respond to steroids; as a result, we feel that race alone should not be an issue in initiating therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Prednisone dose",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal dose and duration of therapy are unknown. In many cases, an overall course of treatment of at least six to eight months is required [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/16,23\">",
"     16,23",
"    </a>",
"    ], and complete remission may not be attained for 12 months or longer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/27\">",
"     27",
"    </a>",
"    ]. Shorter courses (&le;two months) result in much lower remission rates (20 to 30 percent) and may have led to the earlier belief that this condition was not steroid responsive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no randomized trials to guide the dose and duration of glucocorticoid therapy. The following dosing recommendations are extrapolated from doses used with apparent success in some of the observational studies and in trials of other renal diseases:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      , 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum dose 60 to 80",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"      <strong>",
"       OR",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      , 2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      every other day (maximum dose 80 to 120",
"      <span class=\"nowrap\">",
"       mg/day)",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We prefer daily dosing for initial therapy in patients with no contraindications, since failure to respond to alternate day dosing would necessitate conversion to daily dosing and result in prolongation of the steroid course. Despite this general recommendation, alternate day dosing may be a better option in patients at higher risk of complications from glucocorticoids.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Monitoring response to and duration of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific guidelines for monitoring the response to therapy, but it seems reasonable to obtain routine blood chemistries, including a plasma creatinine concentration for estimation of GFR, and to follow the urine protein-to-creatinine ratio. During the initial two to three months of therapy, we evaluate for a response (or toxicity) at two to four week intervals. Prior to tapering immunosuppression, we confirm the level of proteinuria with a 24-hour urine collection. Once drug therapy is stabilized",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    is being tapered, we monitor at one- to two- month intervals. (See",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/41/21151?source=see_link\">",
"     \"Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The subsequent management of patients initially treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is based upon the degree and rapidity of response (eg, faster taper for patients who achieve a quick remission), whether full or partial remission is achieved, and the degree of steroid toxicity:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If a complete remission is achieved within 12 weeks, we continue the initial dose of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      for one to two more weeks and then taper the dose over two to three months. One strategy is to switch to alternate day prednisone (double the daily dose but to a maximum of 80 to 120 mg), and then decrease the dose by approximately one-third every two to three weeks.",
"     </li>",
"     <li>",
"      If a partial remission (&ge;50 percent reduction in protein excretion to less than 3.5",
"      <span class=\"nowrap\">",
"       g/day,",
"      </span>",
"      confirmed with two consecutive 24-hour urine collections) is achieved by 12 weeks, we taper",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      slowly over six to nine months. We initially switch to alternate day dosing, and decrease the dose by approximately one-third approximately every six weeks. If proteinuria increases at any time during the taper, we stop the taper, maintain the current prednisone dose, and add",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or, if the estimated GFR is &lt;40",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Cyclosporine'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      For patients who have had a substantial reduction in proteinuria at 12 to 16 weeks but do not meet criteria for partial remission, the decision to continue high-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      or modify therapy is based upon the severity of steroid toxicity, the risk of continued steroid therapy, and whether protein excretion is continuing to fall (a setting in which high-dose prednisone might be continued) or has plateaued on consecutive 24-hour urine collections. Alternatives to daily prednisone include alternate-day prednisone or switching to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      or, if the estimated GFR is &lt;40",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil, with a subsequent prednisone taper. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Cyclosporine'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Patients who have little or no reduction in proteinuria after 12 to 16 weeks of daily",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      are presumed steroid-resistant. In such patients, we prefer to add",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      and switch to alternate day prednisone with a progressive taper in prednisone therapy, reducing the dose by approximately one-third every week. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Steroid-dependent and steroid-resistant FSGS'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Among patients on prolonged",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy, the risk of adrenal suppression during tapering must be considered. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22103?source=see_link\">",
"     \"Glucocorticoid withdrawal\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Glucocorticoid resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, patients who will respond generally start to show some reduction in protein excretion within the first 8 to 12 weeks of therapy. Thus, patients with little or no reduction in protein excretion at 12 to 16 weeks are considered to be steroid-resistant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/9,16,18\">",
"     9,16,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Factors that appear to be associated with a lower likelihood of response to steroids are significant tubulointerstitial disease on renal biopsy (which may reflect secondary FSGS in some cases), and an elevated plasma creatinine concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/5,6,16\">",
"     5,6,16",
"    </a>",
"    ]. In addition, patients with massive proteinuria (&gt;10",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    may be less likely to respond [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/6,29\">",
"     6,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although certain podocin mutations are associated with steroid-resistance in children, the relevance of these findings to adults is uncertain, and we do not test routinely for this mutation.",
"   </p>",
"   <p>",
"    At present, it is not possible to confidently predict at presentation which patients with primary FSGS will respond to steroid therapy. Even the finding of severe tubulointerstitial fibrosis must be interpreted with caution, given the focal nature of the disease. As a result, such patients should receive a trial of glucocorticoids, unless they are at markedly increased risk of steroid-induced side effects or have a substantial reduction in estimated glomerular filtration rate. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Initial immunosuppressive therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tubulointerstitial disease &mdash; The prognostic importance of tubular disease is suggested from the apparent relation between tubular function (as estimated from the rate of excretion of low molecular weight proteins, such as &szlig;2-microglobulin and retinol-binding protein) and the response to therapy. These smaller proteins are normally filtered and then almost entirely reabsorbed in the proximal tubule. Thus, increased excretion in FSGS reflects tubular dysfunction rather than enhanced glomerular permeability. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=see_link\">",
"       \"Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      In a report of 37 adults with the idiopathic nephrotic syndrome (many of whom had FSGS), those who had little or no low molecular weight proteinuria all went into remission with a 12-week course of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      &nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/30\">",
"       30",
"      </a>",
"      ]. In comparison, increasing degrees of low molecular weight proteinuria carried an increasing likelihood of steroid-resistance. Unfortunately, these measurements are not routinely available. In addition, some patients with tubular proteinuria were steroid-responsive, limiting the prognostic utility of tubular proteinuria.",
"     </li>",
"     <li>",
"      Genetic factors &mdash; Steroid resistance is present in some of the familial forms of FSGS in which mutations involve proteins related to the glomerular podocyte. In addition to familial disease, mutations in the gene (NPHS2) for at least one of these proteins, podocin, have been described in approximately 25 percent of cases of apparently sporadic steroid-resistant FSGS in children from Europe and the Middle East. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H23#H23\">",
"       \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Genetic disease'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      The applicability of these observations to adults and to other populations is under active investigation. One study has suggested that expression of a specific variant of NPHS2 is associated with steroid-resistant adult onset FSGS among patients from European or South America. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H27#H27\">",
"       \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'NPHS2 gene'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Routine testing for this variant among steroid resistant patients is not recommended, however. (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link\">",
"       \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=see_link\">",
"       \"Treatment of idiopathic nephrotic syndrome in children\"",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Additional genetic as well as socioeconomic factors may contribute to treatment resistance [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/31,32\">",
"       31,32",
"      </a>",
"      ]. As an example, the significantly lower response to therapy among African-Americans compared with Caucasians may be due to a variety of factors, including a higher frequency of the collapsing variant, a higher incidence and severity of hypertension, a greater likelihood of presenting with significant fibrosis on biopsy, and possible effects of socioeconomic status on adherence.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Calcineurin inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients at increased risk for glucocorticoid-associated toxicity, we occasionally use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    in conjunction with low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    as initial therapy, although data evaluating this strategy are limited. We avoid using calcineurin inhibitors in patients who have significant vascular or interstitial disease on renal biopsy, or an estimated GFR &lt;40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 because of the nephrotoxicity of these drugs.",
"   </p>",
"   <p>",
"    Studies on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    are restricted to steroid-resistant or steroid-dependent primary FSGS, while there is only one uncontrolled study of initial therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    . In this report, six patients with a mean protein excretion of 11",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    who were being treated with an ACE inhibitor or ARB but no immunosuppression received tacrolimus (initial dose 2 mg twice daily, adjusted to 12-hour trough levels of 4 to 7",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/33\">",
"     33",
"    </a>",
"    ]. All entered a partial remission with &gt;75 percent reduction in proteinuria (to a mean of 2.8",
"    <span class=\"nowrap\">",
"     g/day)",
"    </span>",
"    within a mean of six months. GFR declined initially in two patients from &gt;90 to 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, but subsequently stabilized. The optimal duration of therapy with this approach is uncertain.",
"   </p>",
"   <p>",
"    We favor the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    rather than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    based upon more extensive experience with its use. The dose and monitoring regimen is the same as that used for steroid-dependent and steroid-resistant disease. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Cyclosporine'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H19\">",
"     'Tacrolimus'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Relapsing disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following cessation of initial therapy, some patients experience a recurrence of nephrotic range proteinuria. The approach to this problem varies with the response to initial therapy and the time to relapse:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the patient previously had a complete or partial response to steroids, has not had significant side effects, and has been in remission for more than one year after",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      has been discontinued, we repeat a course of prednisone. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Initial immunosuppressive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients who previously had a complete or partial response to steroids but relapse during the taper or less than one year after cessation of steroid therapy are considered steroid-dependent and are treated as described in the next section.",
"     </li>",
"     <li>",
"      If the patient has had significant steroid-induced toxicity or has subsequent relapses, we usually treat initially with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (3.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, divided in two doses) and low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      , using a similar regimen as described for steroid-dependent or steroid-resistant FSGS. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Cyclosporine'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Steroid-dependent and steroid-resistant FSGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recommendations for the therapy of steroid-dependent and steroid-resistant FSGS are based upon a few randomized controlled trials examining the benefits of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    versus placebo and other agents, as well as observational and uncontrolled studies.",
"   </p>",
"   <p>",
"    FSGS is considered steroid-dependent if a patient relapses while on therapy (or requires continuation of steroids to maintain remission) and steroid-resistant if there is little or no reduction in proteinuria after 12 to 16 weeks of adequate",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    therapy or if there is some reduction in proteinuria with more prolonged therapy that does not meet the criteria for partial remission. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Response to therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We suggest that initial therapy of steroid-dependent or steroid-resistant FSGS consist of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    combined with low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . Among those unresponsive to this combination, additional agents have been evaluated, including",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/34\">",
"     34",
"    </a>",
"    ]. We prefer mycophenolate due to its lower toxicity compared with cyclophosphamide and greater clinical experience than with sirolimus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Cyclosporine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Randomized controlled trials and uncontrolled studies cited below have demonstrated the effectiveness of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in reducing proteinuria in steroid-dependent and steroid-resistant FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/6,22,35-39\">",
"     6,22,35-39",
"    </a>",
"    ]. The reported response rates in steroid-resistant disease range from 20 to 70 percent; however, efficacy in preventing progression to ESRD is unknown.",
"   </p>",
"   <p>",
"    Thus, a trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    is warranted in patients with steroid-dependent or steroid-resistant FSGS, particularly in those with marked or symptomatic nephrotic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/40\">",
"     40",
"    </a>",
"    ]. However, we avoid using cyclosporine or other calcineurin inhibitors in patients who have significant vascular or interstitial disease on renal biopsy or an estimated GFR &lt;40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2, given the potential nephrotoxicity of these drugs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in FSGS occurs earlier (within three months) than the response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    , although the rate of complete (versus partial) remission appears to be lower than with glucocorticoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/16,22,38\">",
"     16,22,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Despite initial benefit, relapses are common after cessation of short-term therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , although long-term kidney function is preserved. The likelihood of relapse appears to be lower if cyclosporine treatment is prolonged, perhaps up to one year or longer after remission is induced, and then gradually tapered and discontinued [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/35\">",
"     35",
"    </a>",
"    ]. However, the risk of cyclosporine nephrotoxicity with prolonged therapy, particularly if the dose is &ge;5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day, must be weighed against potential benefits [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/35,38,40\">",
"     35,38,40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following randomized trials illustrate the efficacy of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    among adults with steroid-resistant FSGS:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a randomized, placebo-controlled study of 49 adults with steroid-resistant FSGS (including 40 percent resistant to cytotoxic therapy), all received low-dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, with a maximum daily dose of 15 mg), and either",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      (initial dose 3.5",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      adjusted to maintain a whole blood trough level between 125 and 225",
"      <span class=\"nowrap\">",
"       mcg/L)",
"      </span>",
"      or placebo for 26 weeks, which was then tapered over four weeks [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/22\">",
"       22",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      At 26 weeks, partial or complete remission of proteinuria was much more frequent with cyclosporine (70 versus 4 percent with placebo). However, relapse was common after cyclosporine withdrawal (40 and 60 percent had worsening of proteinuria by week 52 and 78, respectively). Nevertheless, at four years, active therapy was associated with a lower risk of a 50 percent reduction in creatinine clearance (25 versus 52 percent).",
"     </li>",
"     <li>",
"      In a second trial, 45 adults and children primarily with steroid-resistant FSGS were randomly assigned to supportive therapy or to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      at a dose of 5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in adults and 6",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day in children for six months, then tapered by 25 percent every two months until discontinuation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/38\">",
"       38",
"      </a>",
"      ]. Complete or partial remission was significantly more common with cyclosporine (59 versus 16 percent with supportive therapy). Positive responses occurred as early as two weeks and almost all occurred within two months after the onset of therapy; lack of an antiproteinuric effect at",
"      <strong>",
"       three months",
"      </strong>",
"      was generally indicative of resistance to cyclosporine.",
"     </li>",
"     <li>",
"      A third trial compared",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"       chlorambucil",
"      </a>",
"      in 57 patients with steroid-resistant primary FSGS [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/39\">",
"       39",
"      </a>",
"      ]. Patients were assigned to cyclosporine (5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, adjusted to trough levels between 130 and 180",
"      <span class=\"nowrap\">",
"       ng/mL)",
"      </span>",
"      or chlorambucil (0.1 to 0.4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day) for 6 to 12 weeks, followed by cyclosporine if there was no response. All patients in the chlorambucil group required cyclosporine, suggesting this cytotoxic agent is of no benefit in steroid resistant FSGS. Although there were no differences between groups in the incidence of complete remission (approximately 20 percent), partial remission (approximately 40 percent), or renal survival at four years (83 percent) all patients had received cyclosporine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these observations, we treat with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and concurrent low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Initiate",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      at a dose of approximately 2 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (given in two divided doses) or approximately 100 mg twice daily. We continue cyclosporine for at least six months following attainment of a complete remission and one year following attainment of a partial remission, but at the lowest dose required to maintain the remission (preferably &le;3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day).",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       Prednisone",
"      </a>",
"      is given concurrently at a dose of 0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum 15",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      After six months, we taper prednisone to 5 or 7.5",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      (or 10 to 15 mg on alternate days), and maintain it along with the",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      for an additional 6 to 12 months after attaining a remission. In patients with significant steroid toxicity, we taper prednisone earlier and to discontinuation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We monitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    levels periodically to ascertain absorption and avoid higher, more nephrotoxic levels (ie, keep the level between 100 and 175",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/33,39\">",
"     33,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Tacrolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited experience with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    for the treatment of FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/33,41-44\">",
"     33,41-44",
"    </a>",
"    ]. The largest study was an open-label uncontrolled study consisting of 25 patients (mean proteinuria of 10.2",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and plasma creatinine concentration of 1.2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [106",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/42\">",
"     42",
"    </a>",
"    ]. The patients were resistant to or dependent upon",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and glucocorticoids and were given tacrolimus plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    for six months. Seventeen patients had a reduction in proteinuria to &lt;3",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and 12 had complete or partial remission. Thirteen relapsed after discontinuation of tacrolimus; reinstitution of therapy for one year resulted in complete and partial remission in five and four patients, respectively. Reversible mild acute nephrotoxicity occurred in 40 percent of patients and appeared to be associated with an inappropriately high starting dose.",
"   </p>",
"   <p>",
"    In summary,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    may be of benefit in some patients with FSGS, but its efficacy compared to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    has not been evaluated. Studies in transplant recipients suggest that the efficacy and nephrotoxicity of the two drugs are similar. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=see_link\">",
"     \"Cyclosporine and tacrolimus nephrotoxicity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Mycophenolate mofetil",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/45-48\">",
"     45-48",
"    </a>",
"    ] have suggested a benefit of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (MMF) given with or without glucocorticoids in patients with FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/45-48\">",
"     45-48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One randomized trial has tested the efficacy of MMF and high dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/49\">",
"     49",
"    </a>",
"    ]. The FSGS-Clinical trial (FSGS-CT) was an NIH-funded multicenter trial that compared",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil plus oral pulse dexamethasone to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    among 138 patients with steroid-resistant primary FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/49\">",
"     49",
"    </a>",
"    ]. Mycophenolate mofetil was given at 25 to 36",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day; dexamethasone was given at 0.9",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for two consecutive days at the start of weeks 1 through 8, on alternating weeks through week 26 and every four weeks until week 50; and cyclosporine was given at 5 to 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day with target trough levels of 100 to 250",
"    <span class=\"nowrap\">",
"     ng/mL.",
"    </span>",
"    All patients were given",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    0.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every other day for six months.",
"   </p>",
"   <p>",
"    At a follow-up of 12 months, there was no difference between groups in the percentage of patients who achieved partial or complete remission (30 percent with MMF plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    versus 45 percent with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ). There was also no difference in the percentage of patients who had a sustained remission at 26 weeks after the termination of treatment.However, this study has important limitations that hinder its interpretation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/50\">",
"     50",
"    </a>",
"    ]. First, the number of enrolled subjects was smaller than anticipated; whereas the trial was designed to include 500, only 138 patients were actually randomized. As a result, the trial may have been underpowered to detect small but clinically significant benefits associated with cyclosporine.",
"   </p>",
"   <p>",
"    An additional limitation is that the inclusion criteria allowed patients to be defined as glucocorticoid-resistant after only four weeks of glucocorticoid therapy. This may have resulted in an overestimate of the benefit of immunosuppressive therapy since many patients (especially adults) respond to glucocorticoids after 8 to 12 weeks. The trial also included patients with non-nephrotic proteinuria who generally have a good prognosis and in practice would not be considered for immunosuppressive treatment. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Degree of proteinuria'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H10\">",
"     'Initial immunosuppressive therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The permissive eligibility criteria (among the criteria for trial entry was protein excretion &gt;1.0",
"    <span class=\"nowrap\">",
"     grams/day",
"    </span>",
"    as estimated by protein to creatinine ratio) may also have allowed the inclusion of patients with secondary FSGS. This is in contrast to most studies where patients labeled as having primary FSGS have nephrotic-range proteinuria and patients with presumed secondary FSGS have lower levels of protein excretion. The inclusion of patients with secondary FSGS could potentially have lowered the overall response rate that was observed in this trial since such patients generally do not respond to immunosuppressive treatment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link&amp;anchor=H1498484543#H1498484543\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\", section on 'Distinguishing between primary and secondary FSGS'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to this underpowered randomized trial that demonstrated no benefit, some observational studies have suggested a possible benefit of MMF given with or without glucocorticoids:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a retrospective single center study, 18 patients were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil because of steroid-resistance or steroid-dependence with or without",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      progressive renal dysfunction [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/45\">",
"       45",
"      </a>",
"      ]. Mycophenolate (with or without glucocorticoids), given at variable doses for periods of 4 to 24 months, resulted in complete and partial remission of proteinuria in two and six patients, respectively. Overall, it significantly lowered proteinuria (mean initial urine protein to creatinine ratio of 4.7 to a post-treatment ratio of 2.2), stabilized renal function (mean pre- and post-plasma creatinine concentration of 2.3 and 2.5",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [203 and 221",
"      <span class=\"nowrap\">",
"       micromol/L]",
"      </span>",
"      respectively), and permitted glucocorticoids to be withdrawn without relapse in 8 of 12 patients, at least in the short term.",
"     </li>",
"     <li>",
"      In an uncontrolled prospective study, 18 patients with biopsy-proven FSGS and nephrotic-range proteinuria (all resistant to prolonged glucocorticoids and 75 percent to a cytotoxic agent",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a calcineurin inhibitor) were given",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"      mofetil for a mean period of eight months [",
"      <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/48\">",
"       48",
"      </a>",
"      ]. A reduction in proteinuria of at least 50 percent was observed in eight patients (44 percent). Although none had a complete remission in proteinuria, none had an increase in the plasma creatinine concentration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Based upon these limited observations, we suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil (750 to 1000 mg twice daily for six months) be used in patients with FSGS who are resistant to an adequate trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and have not responded or should not be exposed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , or who have a partial response to prednisone",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cyclosporine but have signs of steroid or cyclosporine toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Cytotoxic therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data on the use of cytotoxic drugs for steroid-dependent or steroid-resistant FSGS in adults are limited to a few retrospective observational studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/10,16,33,39,41-43,45-48\">",
"     10,16,33,39,41-43,45-48",
"    </a>",
"    ], and the previously described randomized trial comparing",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     chlorambucil",
"    </a>",
"    to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , which showed no benefit with chlorambucil [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cytotoxic therapy has been used primarily in the treatment of children with relapsing or steroid-dependent idiopathic nephrotic syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/51,52\">",
"     51,52",
"    </a>",
"    ]. In these settings,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    (2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 8 to 12 weeks) induced complete or partial remission in approximately 75 percent of cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/6,51-53\">",
"     6,51-53",
"    </a>",
"    ]. Cyclophosphamide was less effective in patients who were steroid-resistant, with less than 25 percent deriving sustained benefit from an 8- to 12-week course of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/6,52\">",
"     6,52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=see_link\">",
"     \"Treatment of idiopathic nephrotic syndrome in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    in patients with primary FSGS who do not respond to an adequate trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    . However, cyclophosphamide may be considered in patients who have shown a partial response to prednisone (eg, &ge;50 percent reduction in protein excretion) and who have extensive interstitial fibrosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vascular disease on renal pathology and may therefore be at higher risk of calcineurin nephrotoxicity. If used, cyclophosphamide is added before the prednisone has been discontinued, and is administered for 8 to 12 weeks. More prolonged therapy (&gt;12 weeks) is not beneficial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/16,39\">",
"     16,39",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/52/35654?source=see_link\">",
"     Chlorambucil",
"    </a>",
"    is not recommended because of greater toxicity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Sirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a few reports examining the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    in patients with FSGS who had steroid-resistant disease or were intolerant to continuation of high dose steroids. An initial prospective study suggested benefit from sirolimus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/54\">",
"     54",
"    </a>",
"    ]. However, the use of sirolimus in the treatment of FSGS and other primary glomerulopathies may worsen renal function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/55-57\">",
"     55-57",
"    </a>",
"    ]. In one study of six patients with primary FSGS treated with sirolimus, five experienced a significant decline in GFR after seven to nine months of therapy, and none had a remission of proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/55\">",
"     55",
"    </a>",
"    ]. An additional concern is that sirolimus has been associated with the development of proteinuria and FSGS in renal transplant recipients, as well as acute renal failure when used in combination with calcineurin inhibitors. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17562?source=see_link\">",
"     \"Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We do not advocate the use of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    in the treatment of primary FSGS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Plasmapheresis and related modalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;There may be a limited role for plasmapheresis in the treatment of primary FSGS, based in part upon studies in patients who have recurrent FSGS in the renal allograft [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/34,40,58-60\">",
"     34,40,58-60",
"    </a>",
"    ]. In the latter setting, removal of a circulating factor by plasmapheresis or a protein adsorption column can dramatically reduce proteinuria and, in some cases, induce complete remission. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33722?source=see_link\">",
"     \"Focal segmental glomerulosclerosis in the transplanted kidney\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Any benefit in transplant recipients is generally transient, as protein excretion often returns to pretreatment levels within two months. Furthermore, the applicability of data from transplant recipients to patients with primary FSGS is unclear.",
"   </p>",
"   <p>",
"    There are conflicting reports regarding benefits of plasmapheresis in treating primary FSGS. In one uncontrolled study of patients with refractory primary FSGS, the addition of plasmapheresis seemed beneficial in some individuals [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/59\">",
"     59",
"    </a>",
"    ]. Eleven patients with biopsy proven FSGS unresponsive to glucocorticoids and cytotoxic therapy underwent an average of 17 plasmapheresis sessions over approximately 22 weeks. At follow-up at 27 months, a complete or partial response was observed in six and two patients, respectively. Among the complete responders, average proteinuria fell from 5.8 to 0.9",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and the plasma creatinine stabilized.",
"   </p>",
"   <p>",
"    In contrast, a second uncontrolled study reported a relatively poor response rate with plasmapheresis, with only two of eight patients experiencing transient improvement in proteinuria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/60\">",
"     60",
"    </a>",
"    ]. The ongoing immunosuppressive therapy in the first study, compared to no consistent post-plasmapheresis immunosuppression in the second study, may explain these widely discrepant findings.",
"   </p>",
"   <p>",
"    Whether a patient with primary FSGS might respond to plasmapheresis is thought to vary with the presence or absence, and the absolute level, of the circulating permeability factor. The presence of a permeability factor can be assessed via an in-vitro examination, referred to as the GVV-test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/61\">",
"     61",
"    </a>",
"    ]. In this test, the patient's serum is incubated with isolated rat glomeruli in a hypo-oncotic solution. If albumin leakage is increased because of the presence of a permeability factor, the volume of the rat glomeruli is reduced due to concurrent water transfer.",
"   </p>",
"   <p>",
"    In one report, two patients with a positive GVV-test responded to plasma immunoadsorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/62\">",
"     62",
"    </a>",
"    ]; after therapy, no evidence of a circulating permeability factor was found in either individual. However, when measured serially in another study, the levels of the permeability factor in patients with primary FSGS were lower than previously reported for patients with recurrent post-transplant FSGS, were not related to severity of disease, and did not decrease despite clinical response to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The accurate assessment of the role of plasmapheresis and the GVV-test in the management of patients with FSGS requires further evaluation. This test is not routinely used for diagnostic purposes in patients with primary FSGS.",
"   </p>",
"   <p>",
"    Based upon very limited experience, we only consider plasmapheresis in the following settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Severe disease manifestations despite an adequate trial of initial immunosuppressive therapy, in which very high levels of circulating permeability factor have been demonstrated",
"     </li>",
"     <li>",
"      Continued massive proteinuria and hypoalbuminemia despite exposure to an adequate course of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       mycophenolate",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Plasmapheresis should be performed in conjunction with immunosuppression. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38420?source=see_link\">",
"     \"Prescription and technique of therapeutic plasma exchange\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision to treat patients with significantly reduced renal function (eg, GFR &lt;25 to 35",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) should take into consideration the acuity of the renal failure, findings on renal biopsy (eg, presence of significant tubulointerstitial fibrosis and glomerulosclerosis), and the individual patient's risk for adverse consequences related to therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     LDL apheresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several small nonrandomized studies using variable schedules of LDL apheresis in patients with steroid-resistant primary FSGS have demonstrated some benefit in terms of reduction in proteinuria and improvement in serum albumin concentration, at least in short term follow-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/64-68\">",
"     64-68",
"    </a>",
"    ]. Why this might work is unclear, but postulated mechanisms include reduction in oxidized LDL and associated inflammatory cytokines, and improvement in hypercoagulability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Nonimmunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two major nonimmunosuppressive therapies that should be instituted in most patients with primary FSGS are angiotensin converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), and lipid-lowering with a statin. These are also the mainstays of therapy for nonnephrotic patients with primary FSGS and for patients with proteinuric chronic kidney disease in general.",
"   </p>",
"   <p>",
"    Nonsteroidal antiinflammatory drugs (NSAIDs) also may reduce proteinuria, but they are rarely used given their potential to reduce kidney function.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     ACE inhibitors or ARBs",
"    </span>",
"    &nbsp;&mdash;&nbsp;An ACE inhibitor or an ARB should be given to all patients with primary FSGS, even as specific immunosuppressive treatment is undertaken, or as primary therapy for patients with nonnephrotic proteinuria and patients who have other reasons for not receiving immunosuppression.",
"   </p>",
"   <p>",
"    ACE inhibitors reduce proteinuria in patients with both primary and secondary FSGS and rarely induce a remission without immunosuppressive treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/9,69-73\">",
"     9,69-73",
"    </a>",
"    ]. In addition, these drugs slow the rate of progression to kidney failure in patients with proteinuric renal diseases, although such a benefit has not been specifically proven in primary FSGS. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For these reasons, administration of an ACE inhibitor or ARB is recommended for virtually all patients with primary FSGS, in particular for those who do not go promptly into remission with immunosuppressive therapy. Specific goals should be met as described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Lipid-lowering",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperlipidemia, with often dramatic elevations in the serum cholesterol concentration, is commonly present in patients with nephrotic syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"     \"Lipid abnormalities in nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following observations provide the rationale for lipid-lowering therapy with a statin in such patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronic kidney disease is associated with a marked increase in cardiovascular risk, particularly in older patients. As a result, chronic kidney disease is considered a coronary equivalent that should be treated with a statin. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=see_link\">",
"       \"Chronic kidney disease and coronary heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Statin therapy may slow the rate of progressive renal failure. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30824?source=see_link\">",
"       \"Statins and chronic kidney disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, patients with FSGS who have persistent nephrotic syndrome",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic kidney disease should be treated with a statin. Patients also on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    are at increased risk for rhabdomyolysis because of a drug interaction with many statins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"     \"Lipid abnormalities in nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     NSAIDs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among patients who do not respond to immunosuppressive therapy, as many as 60 percent given an NSAID have a marked reduction in proteinuria (50 to 75 percent) that presumably reflects a decline in intraglomerular pressure induced by renal vasoconstriction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/8,74\">",
"     8,74",
"    </a>",
"    ]. Uncontrolled observations suggest that these responders have a lower rate of progressive renal failure, although the true efficacy of these agents remains to be proven [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possibility of precipitating acute renal failure, a known complication of traditional NSAIDs and the newer selective COX-2 inhibitors, has generally precluded use of these drugs for reducing proteinuria and slowing progression of renal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24582?source=see_link\">",
"     \"NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The only circumstance in which we consider NSAIDs in primary FSGS is in patients with massive proteinuria and end-stage renal disease in an attempt to induce medical nephrectomy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited evidence suggests that an orally active antifibrotic agent,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/26/31141?source=see_link\">",
"     pirfenidone",
"    </a>",
"    , may slow the rate of progression in patients with FSGS. In an open-label trial of 21 patients with biopsy-proven FSGS and advanced chronic kidney disease, the rate of decline in kidney function over one year with pirfenidone was compared with that observed with conventional ACE inhibitor and ARB therapy over an equivalent time period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/75\">",
"     75",
"    </a>",
"    ]. Pirfenidone improved the monthly change in GFR from -.61",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 to -.45",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2 and had no effect on either proteinuria or blood pressure. The drug was well tolerated. Further study in controlled trials is required to clarify the role of this agent.",
"   </p>",
"   <p>",
"    The thiazolidinedione",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/26/2472?source=see_link\">",
"     rosiglitazone",
"    </a>",
"    has also been shown to have antifibrotic effects in animal models of FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/76\">",
"     76",
"    </a>",
"    ]. A phase 1 clinical trial (FONT-I) showed that this agent was safe and well tolerated in 11 patients with biopsy-proven FSGS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?33/57/34714/abstract/77\">",
"     77",
"    </a>",
"    ]. Additional studies are in progress (FONT-II).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Role of protein restriction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of a protein-restricted diet in nephrotic syndrome and in chronic kidney disease is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/45/2777?source=see_link\">",
"     \"Protein restriction and progression of chronic kidney disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Complications of therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The toxicities of the immunosuppressive drugs used to treat primary FSGS are described in detail elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Glucocorticoids (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=see_link\">",
"       \"Major side effects of systemic glucocorticoids\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/14/32992?source=see_link\">",
"       tacrolimus",
"      </a>",
"      &nbsp;(see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=see_link\">",
"       \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      &nbsp;(see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=see_link\">",
"       \"General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"       Mycophenolate",
"      </a>",
"      &nbsp;(see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=see_link\">",
"       \"Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Focal segmental glomerulosclerosis (FSGS) may occur either as a primary disease or as a secondary response to glomerular injury. Distinguishing between primary and secondary disease is important because immunosuppressive therapy is indicated in most patients with primary FSGS but not in secondary FSGS. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Treatment'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=see_link\">",
"     \"Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Untreated patients with nephrotic syndrome (proteinuria &gt;3.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    and hypoalbuminemia) due to primary FSGS typically have a progressive course to ESRD. Treatment with glucocorticoids and other immunosuppressive agents can lead to partial and complete proteinuric response rates of almost 70 percent. Patients without nephrotic syndrome are more likely to remit spontaneously, or to have more slowly progressive disease. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Prognosis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The most important predictor of outcome in patients with primary FSGS is the response to initial therapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A complete response is a reduction in proteinuria to &lt;200 to 300",
"      <span class=\"nowrap\">",
"       mg/day.",
"      </span>",
"     </li>",
"     <li>",
"      A partial response in patients presenting with nephrotic range proteinuria is a reduction in proteinuria by &ge;50 percent, and to less than 3.5",
"      <span class=\"nowrap\">",
"       g/day.",
"      </span>",
"     </li>",
"     <li>",
"      A relapse is return of proteinuria to &ge;3.5",
"      <span class=\"nowrap\">",
"       g/day",
"      </span>",
"      in someone who had undergone a complete or partial remission.",
"     </li>",
"     <li>",
"      Steroid-dependence refers to relapse while on steroids or shortly after discontinuation of steroids, or requirement for continuation of steroids to maintain remission.",
"     </li>",
"     <li>",
"      Steroid-resistance refers to little or no reduction in proteinuria after 12 to 16 weeks of adequate",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      therapy, or to some reduction in proteinuria with more prolonged therapy that does not meet the criteria for partial remission.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Over the long-term, there is a much lower rate of renal failure among patients achieving a complete or partial remission, compared with those who are steroid-resistant. Patients with complete remission should not progress to renal failure if they do not relapse. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Response to therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H8\">",
"     'Disease progression'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The therapeutic recommendations that follow",
"    <strong>",
"     do not apply",
"    </strong>",
"    to collapsing FSGS and to secondary FSGS, which are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/3/2104?source=see_link\">",
"     \"HIV-associated nephropathy (HIVAN)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/31/43512?source=see_link\">",
"     \"Collapsing focal segmental glomerulosclerosis not associated with HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Initial immunosuppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend immunosuppressive therapy for nephrotic patients with primary FSGS (",
"    <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"     Grade 1A",
"    </a>",
"    ). The decision to provide immunosuppression to patients with significantly decreased kidney function (eg, GFR &lt;25 to 35",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73 m2) should take into consideration the acuity of the renal failure (suggesting more reversible disease), findings on renal biopsy (eg, presence of significant tubulointerstitial fibrosis and glomerulosclerosis, which suggest less reversible disease), and the individual patient's risk for adverse consequences related to immunosuppression.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (or equivalent) for all patients without contraindications to steroid use (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Our usual approach is to treat with an initial dose of 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (maximum dose of 60 to 80 mg). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Initial immunosuppressive therapy'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The duration of the initial prednisone dose and rapidity of the steroid taper depends upon whether (and how quickly) a complete or partial remission is attained. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Monitoring response to and duration of therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"       cyclosporine",
"      </a>",
"      as initial therapy in patients who cannot tolerate high dose glucocorticoids (eg, poorly controlled diabetes, morbid obesity, severe osteoporosis) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We usually begin with a dose of 2 to 4",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day (given in two divided doses) or approximately 100 mg twice daily, with concurrent low dose",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (0.15",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day, maximum 15",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      We monitor cyclosporine levels periodically to ascertain absorption and avoid higher, more nephrotoxic levels (ie, target levels between 100 and 175",
"      <span class=\"nowrap\">",
"       ng/mL).",
"       <br/>",
"       <br/>",
"       We",
"      </span>",
"      continue cyclosporine for at least six months following attainment of a complete remission, and one year following attainment of a partial remission, but at the lowest dose required to maintain the remission (and preferably &le;3",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day). Prednisone is tapered after six months and may be continued at a lower dose for the duration of cyclosporine therapy. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Cyclosporine'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      We avoid using cyclosporine or other calcineurin inhibitors in patients who have significant vascular or interstitial disease on renal biopsy, or an estimated GFR &lt;40",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m2.",
"     </li>",
"     <li>",
"      We suggest not providing immunosuppressive therapy to patients with nonnephrotic proteinuria (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Patients with preserved kidney function have a relatively good prognosis, whereas those with significant renal dysfunction may have longstanding unrecognized disease or secondary FSGS. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Relapsing disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;A relapse is defined as a return of proteinuria to &ge;3.5",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in someone who had undergone a complete or partial remission.",
"   </p>",
"   <p>",
"    If a patient has recurrence of nephrotic syndrome after a complete response to steroids and has not had significant side effects related to this therapy, we suggest a second course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    &nbsp;(",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Initial immunosuppressive therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    If the patient has had significant steroid-induced toxicity or has subsequent relapses, we suggest treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and low dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    &nbsp;(",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). The same considerations for its use in initial therapy regarding cautions, dose, and duration of therapy apply.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Steroid-resistant or steroid-dependent disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    for the treatment of patients who are resistant to or dependent upon glucocorticoids (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). The same considerations for its use in initial therapy regarding cautions, dose, and duration of therapy apply. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Initial immunosuppressive therapy'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H18\">",
"     'Cyclosporine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We suggest treating with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/29/4569?source=see_link\">",
"     mycophenolate",
"    </a>",
"    mofetil in patients who are resistant to or dependent upon",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    and have not responded or should not be exposed to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    , or in patients who have shown a partial response to prednisone",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cyclosporine but have signs of steroid or cyclosporine toxicity (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). We usually treat with 750 to 1000 mg twice daily for six months. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Mycophenolate mofetil'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We suggest plasmapheresis in combination with immunosuppression only in the rare circumstances described above (",
"    <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"     Grade 2C",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Plasmapheresis and related modalities'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend obtaining routine blood chemistries, including a plasma creatinine concentration for estimation of GFR, and measurement of the urine protein-to-creatinine ratio at two- to four-week intervals during the initial two to three months of therapy. Prior to tapering immunosuppression, we confirm the level of proteinuria with a 24-hour urine collection. Once drug therapy is stabilized",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    is being tapered, we suggest monitoring at one- to two-month intervals. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Monitoring response to and duration of therapy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Nonimmunosuppressive therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;For all patients with FSGS, we recommend treatment with an ACE inhibitor or an ARB (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). ACE inhibitors or ARBs are the principal therapy for nonnephrotic patients and patients not eligible for immunosuppression, and may also be particularly beneficial for nephrotic patients who do not go into a prompt remission following immunosuppressive therapy or who have persistently decreased kidney function. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=see_link\">",
"     \"Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients with persistent nephrotic syndrome",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chronic kidney disease, we suggest lipid lowering with a statin, with the goal of reducing the risk of cardiovascular disease (",
"    <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"     Grade 2B",
"    </a>",
"    ). Patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    and a statin should be monitored for rhabdomyolysis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=see_link\">",
"     \"Lipid abnormalities in nephrotic syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=see_link\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/1\">",
"      D'Agati V. The many masks of focal segmental glomerulosclerosis. Kidney Int 1994; 46:1223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/2\">",
"      Praga M, Morales E, Herrero JC, et al. Absence of hypoalbuminemia despite massive proteinuria in focal segmental glomerulosclerosis secondary to hyperfiltration. Am J Kidney Dis 1999; 33:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/3\">",
"      Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 15-1983. A 24-year-old man with cervical lymphadenopathy and the nephrotic syndrome. N Engl J Med 1983; 308:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/4\">",
"      Deegens JK, Assmann KJ, Steenbergen EJ, et al. Idiopathic focal segmental glomerulosclerosis: a favourable prognosis in untreated patients? Neth J Med 2005; 63:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/5\">",
"      Rydel JJ, Korbet SM, Borok RZ, Schwartz MM. Focal segmental glomerular sclerosis in adults: presentation, course, and response to treatment. Am J Kidney Dis 1995; 25:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/6\">",
"      Korbet SM, Schwartz MM, Lewis EJ. Primary focal segmental glomerulosclerosis: clinical course and response to therapy. Am J Kidney Dis 1994; 23:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/7\">",
"      Wehrmann M, Bohle A, Held H, et al. Long-term prognosis of focal sclerosing glomerulonephritis. An analysis of 250 cases with particular regard to tubulointerstitial changes. Clin Nephrol 1990; 33:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/8\">",
"      Velosa JA, Torres VE. Benefits and risks of nonsteroidal antiinflammatory drugs in steroid-resistant nephrotic syndrome. Am J Kidney Dis 1986; 8:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/9\">",
"      Korbet SM. Angiotensin antagonists and steroids in the treatment of focal segmental glomerulosclerosis. Semin Nephrol 2003; 23:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/10\">",
"      Cattran DC, Rao P. Long-term outcome in children and adults with classic focal segmental glomerulosclerosis. Am J Kidney Dis 1998; 32:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/11\">",
"      Stirling CM, Mathieson P, Boulton-Jones JM, et al. Treatment and outcome of adult patients with primary focal segmental glomerulosclerosis in five UK renal units. QJM 2005; 98:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/12\">",
"      Abrantes MM, Cardoso LS, Lima EM, et al. Clinical course of 110 children and adolescents with primary focal segmental glomerulosclerosis. Pediatr Nephrol 2006; 21:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/13\">",
"      Troyanov S, Wall CA, Miller JA, et al. Focal and segmental glomerulosclerosis: definition and relevance of a partial remission. J Am Soc Nephrol 2005; 16:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/14\">",
"      Korbet SM. Primary focal segmental glomerulosclerosis. J Am Soc Nephrol 1998; 9:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/15\">",
"      Chitalia VC, Wells JE, Robson RA, et al. Predicting renal survival in primary focal glomerulosclerosis from the time of presentation. Kidney Int 1999; 56:2236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/16\">",
"      Banfi G, Moriggi M, Sabadini E, et al. The impact of prolonged immunosuppression on the outcome of idiopathic focal-segmental glomerulosclerosis with nephrotic syndrome in adults. A collaborative retrospective study. Clin Nephrol 1991; 36:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/17\">",
"      Thomas DB, Franceschini N, Hogan SL, et al. Clinical and pathologic characteristics of focal segmental glomerulosclerosis pathologic variants. Kidney Int 2006; 69:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/18\">",
"      Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants. J Am Soc Nephrol 2004; 15:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/19\">",
"      Stokes MB, Markowitz GS, Lin J, et al. Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum. Kidney Int 2004; 65:1690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/20\">",
"      Beaman M, Howie AJ, Hardwicke J, et al. The glomerular tip lesion: a steroid responsive nephrotic syndrome. Clin Nephrol 1987; 27:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/21\">",
"      Nash MA, Greifer I, Olbing H, et al. The significance of focal sclerotic lesions of glomeruli in children. J Pediatr 1976; 88:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/22\">",
"      Cattran DC, Appel GB, Hebert LA, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int 1999; 56:2220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/23\">",
"      Ponticelli C, Villa M, Banfi G, et al. Can prolonged treatment improve the prognosis in adults with focal segmental glomerulosclerosis? Am J Kidney Dis 1999; 34:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/24\">",
"      Pei Y, Cattran D, Delmore T, et al. Evidence suggesting under-treatment in adults with idiopathic focal segmental glomerulosclerosis. Regional Glomerulonephritis Registry Study. Am J Med 1987; 82:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/25\">",
"      Korbet SM. Treatment of primary focal segmental glomerulosclerosis. Kidney Int 2002; 62:2301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/26\">",
"      Meyrier A. Nephrotic focal segmental glomerulosclerosis in 2004: an update. Nephrol Dial Transplant 2004; 19:2437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/27\">",
"      Pokhariyal S, Gulati S, Prasad N, et al. Duration of optimal therapy for idiopathic focal segmental glomerulosclerosis. J Nephrol 2003; 16:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/28\">",
"      Crook ED, Habeeb D, Gowdy O, et al. Effects of steroids in focal segmental glomerulosclerosis in a predominantly African-American population. Am J Med Sci 2005; 330:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/29\">",
"      Velosa JA, Holley KE, Torres VE, Offord KP. Significance of proteinuria on the outcome of renal function in patients with focal segmental glomerulosclerosis. Mayo Clin Proc 1983; 58:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/30\">",
"      Sesso R, Santos AP, Nishida SK, et al. Prediction of steroid responsiveness in the idiopathic nephrotic syndrome using urinary retinol-binding protein and beta-2-microglobulin. Ann Intern Med 1992; 116:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/31\">",
"      Ingulli E, Tejani A. Racial differences in the incidence and renal outcome of idiopathic focal segmental glomerulosclerosis in children. Pediatr Nephrol 1991; 5:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/32\">",
"      Kao WH, Klag MJ, Meoni LA, et al. MYH9 is associated with nondiabetic end-stage renal disease in African Americans. Nat Genet 2008; 40:1185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/33\">",
"      Duncan N, Dhaygude A, Owen J, et al. Treatment of focal and segmental glomerulosclerosis in adults with tacrolimus monotherapy. Nephrol Dial Transplant 2004; 19:3062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/34\">",
"      Matalon A, Valeri A, Appel GB. Treatment of focal segmental glomerulosclerosis. Semin Nephrol 2000; 20:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/35\">",
"      Meyrier A, No&euml;l LH, Auriche P, Callard P. Long-term renal tolerance of cyclosporin A treatment in adult idiopathic nephrotic syndrome. Collaborative Group of the Soci&eacute;t&eacute; de N&eacute;phrologie. Kidney Int 1994; 45:1446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/36\">",
"      Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr 1994; 125:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/37\">",
"      Lieberman KV, Tejani A. A randomized double-blind placebo-controlled trial of cyclosporine in steroid-resistant idiopathic focal segmental glomerulosclerosis in children. J Am Soc Nephrol 1996; 7:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/38\">",
"      Ponticelli C, Rizzoni G, Edefonti A, et al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int 1993; 43:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/39\">",
"      Heering P, Braun N, M&uuml;llejans R, et al. Cyclosporine A and chlorambucil in the treatment of idiopathic focal segmental glomerulosclerosis. Am J Kidney Dis 2004; 43:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/40\">",
"      Burgess E. Management of focal segmental glomerulosclerosis: evidence-based recommendations. Kidney Int Suppl 1999; 70:S26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/41\">",
"      McCauley J, Shapiro R, Ellis D, et al. Pilot trial of FK 506 in the management of steroid-resistant nephrotic syndrome. Nephrol Dial Transplant 1993; 8:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/42\">",
"      Segarra A, Vila J, Pou L, et al. Combined therapy of tacrolimus and corticosteroids in cyclosporin-resistant or -dependent idiopathic focal glomerulosclerosis: a preliminary uncontrolled study with prospective follow-up. Nephrol Dial Transplant 2002; 17:655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/43\">",
"      Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol 2004; 19:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/44\">",
"      Li X, Li H, Ye H, et al. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR. Am J Kidney Dis 2009; 54:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/45\">",
"      Choi MJ, Eustace JA, Gimenez LF, et al. Mycophenolate mofetil treatment for primary glomerular diseases. Kidney Int 2002; 61:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/46\">",
"      Day CJ, Cockwell P, Lipkin GW, et al. Mycophenolate mofetil in the treatment of resistant idiopathic nephrotic syndrome. Nephrol Dial Transplant 2002; 17:2011.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/47\">",
"      Montan&eacute; B, Abitbol C, Chandar J, et al. Novel therapy of focal glomerulosclerosis with mycophenolate and angiotensin blockade. Pediatr Nephrol 2003; 18:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/48\">",
"      Cattran DC, Wang MM, Appel G, et al. Mycophenolate mofetil in the treatment of focal segmental glomerulosclerosis. Clin Nephrol 2004; 62:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/49\">",
"      Gipson DS, Trachtman H, Kaskel FJ, et al. Clinical trial of focal segmental glomerulosclerosis in children and young adults. Kidney Int 2011; 80:868.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/50\">",
"      Deegens JK, Wetzels JF. Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial. Kidney Int 2011; 80:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/51\">",
"      Siegel NJ, Gaudio KM, Krassner LS, et al. Steroid-dependent nephrotic syndrome in children: histopathology and relapses after cyclophosphamide treatment. Kidney Int 1981; 19:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/52\">",
"      Schulman SL, Kaiser BA, Polinsky MS, et al. Predicting the response to cytotoxic therapy for childhood nephrotic syndrome: superiority of response to corticosteroid therapy over histopathologic patterns. J Pediatr 1988; 113:996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/53\">",
"      Cyclophosphamide treatment of steroid dependent nephrotic syndrome: comparison of eight week with 12 week course. Report of Arbeitsgemeinschaft f&uuml;r P&auml;diatrische Nephrologie. Arch Dis Child 1987; 62:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/54\">",
"      Tumlin JA, Miller D, Near M, et al. A prospective, open-label trial of sirolimus in the treatment of focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2006; 1:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/55\">",
"      Fervenza FC, Fitzpatrick PM, Mertz J, et al. Acute rapamycin nephrotoxicity in native kidneys of patients with chronic glomerulopathies. Nephrol Dial Transplant 2004; 19:1288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/56\">",
"      Cho, M, Hurley, JK, Kopp, JB. Sirolimus for focal segmental glomerulosclerosis. J Am Soc Nephrol 2005; 16:775A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/57\">",
"      Cho ME, Hurley JK, Kopp JB. Sirolimus therapy of focal segmental glomerulosclerosis is associated with nephrotoxicity. Am J Kidney Dis 2007; 49:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/58\">",
"      Ginsburg DS, Dau P. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis. Clin Nephrol 1997; 48:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/59\">",
"      Mitwalli AH. Adding plasmapheresis to corticosteroids and alkylating agents: does it benefit patients with focal segmental glomerulosclerosis? Nephrol Dial Transplant 1998; 13:1524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/60\">",
"      Feld SM, Figueroa P, Savin V, et al. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am J Kidney Dis 1998; 32:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/61\">",
"      Godfrin Y, Dantal J, Bouhours JF, et al. A new method of measuring albumin permeability in isolated glomeruli. Kidney Int 1996; 50:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/62\">",
"      Haas M, Godfrin Y, Oberbauer R, et al. Plasma immunadsorption treatment in patients with primary focal and segmental glomerulosclerosis. Nephrol Dial Transplant 1998; 13:2013.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/63\">",
"      Cattran D, Neogi T, Sharma R, et al. Serial estimates of serum permeability activity and clinical correlates in patients with native kidney focal segmental glomerulosclerosis. J Am Soc Nephrol 2003; 14:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/64\">",
"      Muso E, Mune M, Fujii Y, et al. Significantly rapid relief from steroid-resistant nephrotic syndrome by LDL apheresis compared with steroid monotherapy. Nephron 2001; 89:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/65\">",
"      Stenvinkel P, Alvestrand A, Angelin B, Eriksson M. LDL-apheresis in patients with nephrotic syndrome: effects on serum albumin and urinary albumin excretion. Eur J Clin Invest 2000; 30:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/66\">",
"      Hattori M, Chikamoto H, Akioka Y, et al. A combined low-density lipoprotein apheresis and prednisone therapy for steroid-resistant primary focal segmental glomerulosclerosis in children. Am J Kidney Dis 2003; 42:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/67\">",
"      Nakamura T, Sugaya T, Kawagoe Y, et al. Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis. Clin Nephrol 2006; 65:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/68\">",
"      Muso E, Mune M, Yorioka N, et al. Beneficial effect of low-density lipoprotein apheresis (LDL-A) on refractory nephrotic syndrome (NS) due to focal glomerulosclerosis (FGS). Clin Nephrol 2007; 67:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/69\">",
"      Praga M, Hern&aacute;ndez E, Montoyo C, et al. Long-term beneficial effects of angiotensin-converting enzyme inhibition in patients with nephrotic proteinuria. Am J Kidney Dis 1992; 20:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/70\">",
"      Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/71\">",
"      Ferder LF, Inserra F, Daccordi H, Smith RD. Enalapril improved renal function and proteinuria in chronic glomerulopathies. Nephron 1990; 55 Suppl 1:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/72\">",
"      Crenshaw G, Bigler S, Salem M, Crook ED. Focal segmental glomerulosclerosis in African Americans: effects of steroids and angiotensin converting enzyme inhibitors. Am J Med Sci 2000; 319:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/73\">",
"      Stiles KP, Abbott KC, Welch PG, Yuan CM. Effects of angiotensin-converting enzyme inhibitor and steroid therapy on proteinuria in FSGS: a retrospective study in a single clinic. Clin Nephrol 2001; 56:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/74\">",
"      Vriesendorp R, Donker AJ, de Zeeuw D, et al. Effects of nonsteroidal anti-inflammatory drugs on proteinuria. Am J Med 1986; 81:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/75\">",
"      Cho ME, Smith DC, Branton MH, et al. Pirfenidone slows renal function decline in patients with focal segmental glomerulosclerosis. Clin J Am Soc Nephrol 2007; 2:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/76\">",
"      Weissgarten J, Berman S, Efrati S, et al. Apoptosis and proliferation of cultured mesangial cells isolated from kidneys of rosiglitazone-treated pregnant diabetic rats. Nephrol Dial Transplant 2006; 21:1198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?33/57/34714/abstract/77\">",
"      Joy MS, Gipson DS, Dike M, et al. Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group. Clin J Am Soc Nephrol 2009; 4:39.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3100 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-4A54400AA2-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_57_34714=[""].join("\n");
var outline_f33_57_34714=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Prognostic factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Degree of proteinuria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Severity of renal dysfunction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Histologic findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Response to therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Disease progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Initial immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Glucocorticoid studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Prednisone dose",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Monitoring response to and duration of therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Glucocorticoid resistance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Calcineurin inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Relapsing disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Steroid-dependent and steroid-resistant FSGS",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Cyclosporine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Mycophenolate mofetil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Cytotoxic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Sirolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Plasmapheresis and related modalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - LDL apheresis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Nonimmunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - ACE inhibitors or ARBs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Lipid-lowering",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - NSAIDs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Other agents",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Role of protein restriction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Complications of therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Initial immunosuppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Relapsing disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Steroid-resistant or steroid-dependent disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Nonimmunosuppressive therapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/3100\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/3100|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?8/53/9050\" title=\"picture 1\">",
"      Early FGS Tip lesion Light",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/10/41130?source=related_link\">",
"      Antihypertensive therapy and progression of nondiabetic chronic kidney disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/37/13914?source=related_link\">",
"      Assessment of urinary protein excretion and evaluation of isolated non-nephrotic proteinuria in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/31/34298?source=related_link\">",
"      Chronic kidney disease and coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/31/43512?source=related_link\">",
"      Collapsing focal segmental glomerulosclerosis not associated with HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/61/41945?source=related_link\">",
"      Cyclosporine and tacrolimus nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/6/41066?source=related_link\">",
"      Epidemiology, classification, and pathogenesis of focal segmental glomerulosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/59/33722?source=related_link\">",
"      Focal segmental glomerulosclerosis in the transplanted kidney",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/32/25098?source=related_link\">",
"      General toxicity of cyclophosphamide and chlorambucil in inflammatory diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/37/22103?source=related_link\">",
"      Glucocorticoid withdrawal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/3/2104?source=related_link\">",
"      HIV-associated nephropathy (HIVAN)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/41/33430?source=related_link\">",
"      Lipid abnormalities in nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/9/17562?source=related_link\">",
"      Mammalian target of rapamycin (mTOR) inhibitors in renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/50/2855?source=related_link\">",
"      Mycophenolate mofetil: Pharmacology and adverse effects when used in the treatment of rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/0/24582?source=related_link\">",
"      NSAIDs: Acute kidney injury (acute renal failure) and nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/41/21151?source=related_link\">",
"      Patient information: Collection of a 24-hour urine specimen (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/33/38420?source=related_link\">",
"      Prescription and technique of therapeutic plasma exchange",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/45/2777?source=related_link\">",
"      Protein restriction and progression of chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/6/30824?source=related_link\">",
"      Statins and chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/15/28922?source=related_link\">",
"      Treatment of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f33_57_34715="Frequency of mutant alleles";
var content_f33_57_34715=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77985&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of the frequency of mutant alleles in 227 North Americans with galactosemia (each patient has two alleles)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Mutant alleles",
"       </td>",
"       <td class=\"subtitle1\">",
"        Caucasian",
"       </td>",
"       <td class=\"subtitle1\">",
"        Hispanic",
"       </td>",
"       <td class=\"subtitle1\">",
"        African-American",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Q188R",
"       </td>",
"       <td>",
"        257 (64 percent)",
"       </td>",
"       <td>",
"        24 (50 percent)",
"       </td>",
"       <td>",
"        22 (21 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S135L",
"       </td>",
"       <td>",
"        6 (1.5 percent)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        49 (47 percent)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N314D",
"       </td>",
"       <td>",
"        4 (1 percent)",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"       <td>",
"        135 (33.5 percent)",
"       </td>",
"       <td>",
"        24 (50 percent)",
"       </td>",
"       <td>",
"        33 (32 percent)",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        <strong>",
"         Total alleles",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         402",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         48",
"        </strong>",
"       </td>",
"       <td>",
"        <strong>",
"         104",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    While certain alleles are common, a significant portion are rare or unidentified.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wong, LJ, Xu, YK, Wang, BT, et al. Am J Hum Genet 1996; 59:A296. Copyright &copy; 1996 The University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_57_34715=[""].join("\n");
var outline_f33_57_34715=null;
var title_f33_57_34716="F-75 and F-100 Diets";
var content_f33_57_34716=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F74062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F74062&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=7\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Preparation of F-75 and F-100 diets used in the treatment of malnutrition in children",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Ingredient",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Amount",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        F-75*",
"        <sup>",
"         &bull;&Delta;",
"        </sup>",
"       </td>",
"       <td class=\"subtitle2\">",
"        F-100",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dried skimmed milk",
"       </td>",
"       <td>",
"        25 g",
"       </td>",
"       <td>",
"        80 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sugar",
"       </td>",
"       <td>",
"        70 g",
"       </td>",
"       <td>",
"        50 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cereal flour",
"       </td>",
"       <td>",
"        35 g",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vegetable oil",
"       </td>",
"       <td>",
"        27 g",
"       </td>",
"       <td>",
"        60 g",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mineral mix",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        20 mL",
"       </td>",
"       <td>",
"        20 mL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Vitamin mix",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        140 mg",
"       </td>",
"       <td>",
"        140 mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Water to make",
"       </td>",
"       <td>",
"        1000 mL",
"       </td>",
"       <td>",
"        1000 mL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * To prepare the F-75 diet, add the dried skimmed milk, sugar, cereal flour and oil to some water and mix. Boil for 5-7 minutes. Allow to cool, then add the mineral mix and vitamin mix and mix again. Make up the volume to 1000 mL with water.&nbsp;A comparable formula can be made from 35 g of whole dried milk, 70 g of sugar, 35 g of cereal flour, 17 g of oil, 20 ml of mineral mix, 140 mg of vitamin mix and water to make 1000 mL.&nbsp;",
"     <br>",
"      &bull; If cereal flour is not available or there are no cooking facilities, a comparable formula can be made from 25 g of dried skimmed milk, 100 g of sugar, 27 g of oil, 20 mL of mineral mix, 140 mg of vitamin mix and water to make 1000 mL. However, this formula has a high osmolarity (415 mOsmol/L) and may not be well tolerated by all children, especially those with diarrhoea.",
"      <br>",
"       &Delta; Isotonic versions of F-75 (280 mOsmol/L), which contain maltodextrins instead of cereal flour and some of the sugar and which include all the necessary micronutrients, are available commercially.",
"       <br>",
"        &loz;&nbsp;To prepare the F-100 diet, add the dried skimmed milk, sugar and oil to some warm boiled water and mix. Add the mineral mix and vitamin mix and mix again. Make up the volume to 1000mL with water.",
"        <br>",
"         &sect;&nbsp;See related tables describing the WHO Vitamin mix and WHO Mineral mix. If only small amounts of feed are being prepared, it will not be feasible to prepare the vitamin mix because of the small amounts involved. In this case, give a proprietary multivitamin supplement. Alternatively, a combined mineral and vitamin mix for malnourished children is available commercially and can be used in the above diets.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Management of Severe Malnutrition: A Manual for Physicians and other Senior Health Workers. World Health Organization, Geneva, 1999. Copyright &copy;1999 World Health Organization.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_57_34716=[""].join("\n");
var outline_f33_57_34716=null;
var title_f33_57_34717="History reading difficulty";
var content_f33_57_34717=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F58064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F58064&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Important aspects of the history in a child with reading difficulty",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Feature",
"       </td>",
"       <td class=\"subtitle1\">",
"        Clinical implications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Perinatal history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Maternal drug or alcohol intake",
"       </td>",
"       <td>",
"        May cause neurologic problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Congenital infections",
"       </td>",
"       <td>",
"        May cause neurologic or hearing problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gestational age, birth weight",
"       </td>",
"       <td>",
"        Premature birth is a risk for learning disability",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Medical history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Recurrent or persistent ear infections",
"       </td>",
"       <td>",
"        May be associated with hearing impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Iron deficiency",
"       </td>",
"       <td>",
"        Associated with neurologic deficits",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lead poisoning",
"       </td>",
"       <td>",
"        Associated with neurologic deficits and hearing impairment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Seizures",
"       </td>",
"       <td>",
"        May be associated with neurologic problems",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Frequent injuries",
"       </td>",
"       <td>",
"        May indicate coordination difficulties, history of closed head injury, poor supervision, and/or environmental deprivation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chronic illness or medication usage",
"       </td>",
"       <td>",
"        May be associated with side effects or school absences with secondary effects on learning",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Developmental history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Delayed or disordered acquisition of language milestones and communication skills",
"       </td>",
"       <td>",
"        Language delay is a risk for reading difficulty",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Uneven pattern of skills and interests",
"       </td>",
"       <td>",
"        May indicate learning disability",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Behavioral history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Problems with attention, impulsivity, overactivity, acting out",
"       </td>",
"       <td>",
"        Behavioral problems may affect learning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sadness",
"       </td>",
"       <td>",
"        Emotional problems may affect learning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Poor self-esteem",
"       </td>",
"       <td>",
"        May be a consequence of reading difficulty",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Social history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Child abuse or neglect, or other social stressors (eg, homelessness, poverty, illness in family member)",
"       </td>",
"       <td>",
"        These stressors may affect learning",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Family history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Learning problems, reading or spelling problems, avoidance of reading, school failure among first-degree relatives",
"       </td>",
"       <td>",
"        Increases risk of reading disability",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        School history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Academic achievement",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Best and worst subjects",
"       </td>",
"       <td>",
"        Children with reading disability may excel in other areas or areas of interest (eg, math, science)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        History of grade retention",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Classroom behavior",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Long-standing problems with attention, impulsivity, overactivity",
"       </td>",
"       <td>",
"        Reading disability is associated with attention deficit hyperactivity disorder, which can further interfere with school function",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Depression, moodiness",
"       </td>",
"       <td>",
"        Emotional problems may affect learning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Behavior differs in reading versus other subjects",
"       </td>",
"       <td>",
"        Children with reading difficulty may \"act out\" during activities that require reading",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Attendance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Excessive absenteeism",
"       </td>",
"       <td>",
"        Frequent absences may affect learning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        School avoidance",
"       </td>",
"       <td>",
"        Children with reading difficulty may try to avoid school",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Past psychoeducational testing",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Discrepancy between cognitive abilities and academic achievement",
"       </td>",
"       <td>",
"        Suggestive of a learning disability",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"2\">",
"        Special educational services",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Response to educational interventions",
"       </td>",
"       <td>",
"        Lack of response suggests a learning disability rather than lack of exposure to reading and or inadequate instruction before formal schooling",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_57_34717=[""].join("\n");
var outline_f33_57_34717=null;
var title_f33_57_34718="Glycogen acanthosis Endosc";
var content_f33_57_34718=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F56274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F56274&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Esophageal glycogen acanthosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 252px; height: 260px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy revealed multiple elevated gray-white nodules (white arrows) in the upper and middle third of the esophagus. A long segment of salmon colored mucosa was seen in the distal esophagus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andres Gelrud, MD and Kenneth Falchuk, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_57_34718=[""].join("\n");
var outline_f33_57_34718=null;
var title_f33_57_34719="Algorithm shoulder pain";
var content_f33_57_34719=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 503px\">",
"   <div class=\"ttl\">",
"    Shoulder pain algorithm",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 483px; height: 588px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     AC: acromioclavicular; DL: dislocation; Fx: fracture; GH: glenohumeral; SL: subluxation.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f33_57_34719=[""].join("\n");
var outline_f33_57_34719=null;
